Background: In many human cancers, abnormalities in genes and proteins that regulate the cell cycle have been demonstrated. For instance, p16
The High Delta Ct Value of EGFR Exon 19 Deletion by PNA-Mediated PCR Clamping Can Predict Longer Progression-Free Survival in Non-Small Cell Lung Cancer
Yu-Deok Choi. Chonnam National University Medical School, Gwangju, Republic of Korea. Background: Epidermal growth factor receptor (EGFR) mutation, such as deletions in exon 19 (19del) and point mutations in exon 21 (L858R) are reliable factors of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). We investigated the quantification of EGFR mutation can predict progression-free survival (PFS) of EGFR-TKIs. Design: We screened 555 cases for EGFR mutations using peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) and found 156 single activating mutations (90 case of 19del and 66 cases of L858R in NSCLC). The efficiency of PCR clamping was determined by measuring the cycle threshold (Ct) value and the EGFR quantification was determined by delta Ct(∆Ct) value which was calculated (wild type control Ct-sample Ct). Results: The median PFS of patients with ∆Ct ≥ 2.0 (371 days, 95% confidence interval [CI] 336-406) had longer tendency as compared with ∆Ct ≤ 2.0 (210 days, 95% CI 53-367, p = 0.280). The median PFS of patients with ∆Ct ≥ 2.0 was significantly longer than patients with ∆Ct < 2.0 in cytology specimen (371 vs. 210 days, p =0.009), but not in biopsy specimen (p = 0.453). In 19del subgroup, the median PFS of patients with ∆Ct ≥ 2.0 (353 days, 95% CI 203 -503 ) was significantly longer than patients with ∆Ct < 2.0 (104 days, 95% CI 0 -251, p <0.001). And theses significant longer median PFS of patients with ∆Ct ≥ 2.0 were shown both in biopsy (p =0.028) and cytology specimen (p < 0.001). Conclusions: Quantification of EGFR mutation by ∆Ct value of PNA-mediated PCR clamping can predict longer PFS of EGFR-TKIs in patients with 19del mutation regardless of specimen types.
Mcl-1 Protein Expression and MCL1 Gene Amplification in Non Small Cell Lung Cancer (NSCLC)
Siddhartha Dalvi, Sungeun Kim, Christine E Sheehan, Jeffrey S Ross. Albany Medical College, Albany, NY. Background: Myeloid cell leukemia 1 (Mcl-1) is a member of the B-cell lymphoma 2 (Bcl-2) family known to play a significant role in the regulation of apoptosis. Mcl-1 expression has been studied in NSCLC cell lines, but has not been previously evaluated as a prognostic factor in clinical samples. In the following study we assessed both Mcl-1 protein expression and MCL1 gene amplification in NSCLC and compared the results with clinicopathologic variables. Design: Formalin-fixed, paraffin embedded sections from 119 NSCLC, including 33 squamous cell carcinomas (SCC), 55 adenocarcinomas (AC), and 31 either pure bronchioloalveolar carcinomas (BAC) or AC with BAC features were immunostained by an automated method (Ventana/Roche, Tucson, AZ) with rabbit polyclonal Mcl-1 (clone S-19, Santa Cruz). Cytoplasmic (cMcl-1) immunoreactivity was scored based on intensity and percentage of positive tumor cells in both the tumor and adjacent benign epithelium in each case. Scoring was based on staining intensity (weak, moderate, intense) and percentage of positive cells (focal <= 10%, regional 11-50%, diffuse >50%). MCL1 gene amplification was determined by hybrid capture based comprehensive genomic profiling (CGP) on a separate cohort of 9,393 NSCLC samples. Results: Intense diffuse cMcl-1 overexpression was noted in 35/119 (29%) tumors overall and correlated with tumor type [52% BAC vs 31% AC vs. 6% SCC, p<0.0001], tumor grade [48% grade 1 vs 14% grade 2 vs 31% grade 3, p=0.007], small tumor size [36% <= 3.0 cm vs 16% > 3.0cm, p=0.016], and lengthened survival within the BAC subgroup [100% alive vs 42% expired, p=0.018]; while showing a trend toward correlation with non-recurrent disease overall [32% non-recurrent vs 11% recurrent, p=0.072] and within the AC subgroup [33% non-recurrent vs 0% recurrent, p=0.092]. MCL1 gene amplification was identified in 569 (6%) of 9,393 NSCLC by CGP. On multivariate analysis, positive lymph node status (p<0.0001) independently predicted overall survival. Conclusions: cMCL-1 overexpression appears to occur independently from MCL1 gene amplification in NSCLC and correlates with bronchioloalveolar histologic type, lower tumor grade, smaller tumor size, non-recurrent disease, and increased survival. Continued studies are required to learn if cMCL-1 overexpression can be routinely used in surgical pathology practice for predicting prognosis for NSCLC cases.
Fibroblastic foci, known as poor prognostic factor in UIP, did not associate with AE (p=0.3). Significant differences were noted between the prognosis and vital capacity (p<0.01) and squamous metaplasia (p=0.046).
Conclusions:
We found that presence of squamous metaplasia in surgical lung biopsy is an indicator of AE and a poor prognostic factor in UIP.
Immunohistochemical Analysis of p14ARF, p15INK4B, p16INK4A, MTAP, and Their Combinations May Predict the Deletion Status of 9p21 in Malignant Pleural Mesothelioma
Tomoyuki Hida, Makoto Hamasaki, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Yoshinao Oda, Kazuki Nabeshima. Fukuoka University School of Medicine and Hospital, Fukuoka, Japan; Graduate School of Medical Science, Kyushu University, Fukuoka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Osaka Prefectual Medical Center for Respiratory and Allergic Disease, Habikino-shi, Osaka, Japan. Background: Differentiating malignant pleural mesothelioma (MPM) from reactive mesothelial hyperplasia (RMH) is still problematic. Homozygous deletion (HD) of p16 INK4A (p16) , detected by fluorescence in situ hybridization (FISH), is a good marker for MPM in such a setting, but this method cannot be performed in all laboratories. Immunohistochemistry (IHC) is a more common, feasible technique, and a combined loss of methylthioadenosine phosphorylase (MTAP) and p16 expression has been proposed as a surrogate marker for p16 HD in pancreatic and lung cancer. In this study, we investigated whether immunohistochemical detection of the loss of or decrease in expression of the products of genes located in the 9p21 region, such as p14 ARF , p15 INK4B , p16, and MTAP, could predict the deletion status detected by p16 FISH in MPM. Design: Expression levels of p14 ARF , p15 INK4B , p16, and MTAP were investigated immunohistochemically in 35 epithelioid MPM, and concordance between their results and the deletion status of the 9p21 locus as detected by FISH was analyzed statistically. Moreover, we examined combinations of the IHC expression levels of the gene products for concordance with p16 FISH results. Results: By IHC, loss or decreased expression of p14 ARF , p15 INK4B , p16, and MTAP were observed in 30%, 37%, 37%, and 51% of MPM, respectively, while p16 HD was detected in 69% of MPM by FISH. Among the four genes, the results of MTAP IHC showed best accordance with those of p16 FISH (kappa coefficient [k] = 0.65). Moreover, loss or decrease of p15
INK4B
-or-MTAP and that of p16-or-MTAP shown by IHC exhibited much better concordance (k = 0.81 and 0.76, respectively). For predicting p16 HD detected by FISH, loss or decrease of p15
, p16, or MTAP, but not of p14 ARF , showed 100% specificity.
Conclusions: Combinations of p15

INK4B
-or-MTAP and p16-or-MTAP IHC can possibly detect most instances of p16 HD in MPM, and thus could serve as useful ancillary IHC for discriminating MPM from RMH.
Utility of BAP1 FISH and immunohistochemistry in Distinguishing between Mesothelioma and Reactive Mesothelial Proliferation. Comparison with Analysis of p16/CDKN2A
Kenzo Hiroshima, Di Wu, Mizue Hasegawa, Yasuo Sekine, Daisuke Ozaki, Toshikazu Yusa, Zhibin Gao, Ann E Walts, Alberto M Marchevsky, Yuji Tada, Hideaki Shimada, Masatoshi Tagawa. Tokyo Women's Medical University, Yachiyo, Chiba, Japan; Chiba Rosai Hospital, Ichihara, Chiba, Japan; Yuyao People's Hospital, Yuyao, Ningbo, China; Cedars-Sinai Medical Center, Los Angeles, CA; Chiba University, Chiba, Japan; Toho University, Tokyo, Japan; Chiba Cancer Center Research Institute, Chiba, Japan. Background: Distinction between mesothelioma and reactive mesothelial proliferation is sometimes difficult, especially when the biopsy specimen is small. However, correct diagnosis is crucial to patient care and compensation. It is reported that most mesotheliomas have deletion of p16/CDKN2A. Recently, loss of BAP1 expression has been reported in some mesotheliomas. Design: FISH analysis of p16/CDKN2A and immunohistochemistry (IHC) of BAP1 was performed on 47 surgical biopsies from histologically confirmed malignant mesotheliomas. BAP1 stain was also performed on 22 cell block samples (17 mesotheliomas and 5 reactive mesothelial proliferations). FISH analysis of BAP1 gene was performed on tissue sections of 16 mesotheliomas. Results: Homozygous deletion of p16/CDKN2A was observed in 74.3% (26/35) of the mesotheliomas. There was a 100% concordance in CDKN2A deletion status between epithelioid and sarcomatoid components in biphasic mesotheliomas. BAP1 loss was observed in 50% (15/30) of epithelioid mesotheliomas and 33.3% (4/12) of biphasic mesotheliomas, but none (0/5) of sarcomatoid mesotheliomas. BAP1 loss was observed in epithelioid component but not in sarcomatoid component of one of biphasic mesotheliomas. BAP1 was retained in reactive mesothelial proliferations. All of the mesotheliomas with BAP1 loss harbored homozygous deletion of BAP1 gene. However, two mesotheliomas without BAP1 loss harbored homozygous deletion of BAP1 gene. Homozygous deletion of p16/CDKN2A and/or BAP1 loss was observed in 88.6% (31/35) of mesotheliomas. In cell blocks, homozygous deletion of p16/CDKN2A was observed in 76.5% (13/17) and BAP1 loss was observed in 82. 4% (14/17) . Homozygous deletion of p16/CDKN2A and/or BAP1 loss was observed in 88.2% (15/17) of cell blocks. Concordance of the results of homozygous deletion of p16/CDKN2A and BAP1 loss between surgical biopsies and cell blocks of mesothelioma was good. Conclusions: Some of mesotheliomas with homozygous deletion of BAP1 gene maintain BAP1 function. Because there is discrepancy of BAP1 loss in epithelioid and sarcomatoid component, BAP1 loss may be later event. BAP1 FISH and IHC is a good tool for the diagnosis of mesothelioma without p16/CDKN2A deletion on surgical biopsies and on cell blocks.
Non-neoplastic Pulmonary Parenchymal Findings in Patients Undergoing Lung Resection for Mass Lesions
Yin Hung, Gary M Hunninghake, Rachel K Putman, Lynette M Sholl, Marina Vivero. Brigham and Women's Hospital, Boston, MA. Background: Potentially significant non-neoplastic lung disease may be detected in patients undergoing resection for mass lesions, but the incidence of such findings is unknown. We determined the prevalence and characteristics of parenchymal findings in patients with benign and malignant lung nodules, aiming to increase awareness of findings that could potentially impact patient management. Design: The study included 347 lung resections from 340 patients with benign or malignant mass lesions and available pre-surgical computed tomography obtained between January 2001 and July 2015. Histologic assessment of interstitial, pleural, airway, airspace, and vascular abnormalities was correlated with clinical and radiologic abnormalities. Non-neoplastic lung findings were categorized as significant if they could potentially alter pathologic diagnosis or patient management, explain reported symptoms, or account for radiologic findings. Results: 195 women and 145 men (mean age 65.6, range 31.9 to 89.4) underwent resection for carcinomas (256, 74%) or benign nodules (91, 26% ). 86 (25%) specimens showed significant histologic parenchymal abnormalities, most commonly patchy granulomatous inflammation (27 patients, 7.8%) and findings consistent with interstitial lung disease (ILD) (53, 15%) including: smoking-related interstitial fibrosis (SRIF) (26, 7.5%), aspiration (15, 4.3%), undefined ILD (9, 2.6%), Langerhans cell histiocytosis (2), and sarcoidosis (1). Other findings included thrombotic angiopathy (6, 1.7%), misdiagnosis (2), small airway obliteration (1), aspiration and amyloidosis (1), and suspicious lymphoid infiltrates (4). Abnormalities were documented in 28 of 86 original pathology reports (33%), of which 19 (68%) were reviewed by pulmonary pathologists. SRIF and granulomas were the only abnormalities recognized by general pathologists. Clinical correlates to histologic abnormalities were present in 42 of 86 cases (49%), 3 (4%) of which had been diagnosed clinically prior to biopsy. Conclusions: Potentially significant pulmonary parenchymal findings were present in 25% of patients undergoing resections for lung masses at our institution. Despite potential impact on histologic diagnosis and patient management, these findings often go unreported by general pathology practitioners. Increased awareness, education, and judicious use of subspecialty consultation may prevent misdiagnosis or misinterpretation and help improve patient management. Tiffany G Huynh, Justin F Gainor, Valentina Nardi, Mari Mino-Kenudson. Massachusetts General Hospital, Boston, MA. Background: No effective targeted therapies are currently available for lung adenocarcinomas (ADC) with KRAS mutations, the most common oncogenic driver in NSCLC in western patients. We have reported the association of PD-L1 expression with KRAS mutations in ADC, suggesting that PD-1/PD-L1 blockade may be a treatment strategy for KRAS-mutated ADC (K-ADC). However, the majority of K-ADC do not exhibit PD-L1. In addition, multiple studies have shown heterogeneity in therapeutic responsiveness and biology in K-ADC. Thus, we evaluated a cohort of 139 K-ADC with a few biomarkers to classify them into biologically relevant groups. Design: p53, HNF4a, PD-L1 and CD8 IHC were performed on tissue microarray slides or a representative section of biopsy/cytology specimens. p53 nuclear expression was scored using a 3-tiered system (0-2) with 0% and 50% cut-offs, and scores 0 and 2 were deemed abnormal as previously reported. Nuclear expression in >5% of tumor cells was considered positive for HNF4a. Membranous expression in >5% of tumor cells was deemed positive for PD-L1 expression. CD8+ tumor infiltrating lymphocytes (TILs) were scored using a 2-tiered system (0-1). The cohort was classified into p53 abnormal (KP), p53 normal & HNF4a positive (KH) and p53 normal & HNF4a negative (KN) groups. Clinicopathological variables, PD-L1 expression, CD8+ TILs and progression free survival (PFS) were compared between the 3 groups. Results: Of the 139 patients (62 stage I, 14 stage II, 20 stage III, and 43 stage IV), 73, 25 and 41 were classified into the KP, KH and KN groups, respectively. The KP group was associated with advanced stage (IV) (41%, p=0.023 vs. KN), PD-L1 expression (50%, p=0.010 vs. KH, p=0.018 vs. KN) and increased CD8+ TILs (29%, p=0.011 vs. KH, p=0.008 vs. KN), while the KH group was associated with an invasive mucinous adenocarcinoma (IMA) morphology (48%, p=0.0003 vs. KP, p=0.0021 vs. KN). As for survival, the KN group showed a trend towards adverse outcomes with the 3-year PFS being 57%, 74% and 46% for the KP, KH, and KN groups, respectively. Conclusions: K-ADC appear to consist of biologically distinct groups. While those with p53 alterations more likely present at an advanced stage but may be amenable to the PD-1/PD-L1 axis blockade, HNF4a positive tumors more likely exhibit IMA morphology and follow a more indolent clinical course. Those with neither alteration may have addtional abnormalities such as LKB1 loss that is reportedly associated with poor survival in K-ADC. Additional study with LKB1 IHC is underway.
Lung Adenocarcinomas with KRAS Mutations Are Biologically Heterogeneous
Next Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases
Wendy Kadi, Snehal Patel, Jean Lopategui, Ann E Walts, Alberto M Marchevsky, Andy Pao, Tudor Mudalige, Angela Aguiluz. Cedars Sinai Medical Center, Los Angeles, CA. Background: Multifocal lung adenocarcinomas (ACAs) are difficult to stage and pose major problems in patient management. Whereas independent primary lung ACAs are staged individually and treated accordingly, contralateral pulmonary and extrapulmonary metastases are assigned to stage IV and treated with more aggressive therapy. Currently, this distinction is based on clinical, radiologic, and pathologic findings, but these approaches can yield equivocal and/or conflicting conclusions. This study explores the use of next generation sequencing (NGS) to distinguish independent primary lung ACAs from intrapulmonary metastases and facilitate more accurate staging of multiple lung ACAs. Design: Samples of 40 formalin-fixed paraffin-embedded ACAs from 19 patients were selected from our institutional archive: 5 patients with synchronous bilateral lung ACAs (4 pairs, 1 trio), 5 patients with metachronous bilateral lung ACAs (5 pairs), and 9 patients with primary lung ACA/distant metastasis (8 pairs, 1 trio). Samples were analyzed using the Ion AmpliSeq Cancer Hotspot Panel v2 with aberrations filtered to include only non-synonymous amino acid changes in 2855 "hotspots" frequently mutated in 50 cancer-associated genes. Results: All 5 synchronous bilateral ACA pairs/trios had entirely non-overlapping mutations. All 9 primary ACA/distant metastasis pairs/trio had identical or overlapping mutations. Of the 5 metachronous bilateral ACA pairs, the 2 suspected to represent primary/metastatic pairs based on clinicopathologic features had identical or overlapping mutations whereas the 3 suspected to be independent primaries had non-overlapping mutations. Conclusions: Our findings suggest that metastatic and their paired lung primary ACAs harbor identical or overlapping mutations while independent primary lung ACAs display non-overlapping mutations. Future studies are needed to clinically validate NGS as a useful and objective tool in staging multifocal lung cancers as either independent primaries or intrapulmonary metastases.
Prognostic Factors and Recurrence in Primary Lung Carcinoid Tumor Treated at a Single Institution
Neda Kalhor, Guoping Xu, Junya Fujimoto, Francesco Stingo, Bonnie Glisson, Reza J Mehran, James C Yao, Cesar A Moran . MD Anderson Cancer Center, Houston, TX; Dali University, Yunnan, China. Background: Primary Lung Carcinoid Tumors (PLCT) are uncommon neoplasms and formulating a clinically effective prognostic stratification is a challenge and to date, histologic grade remains the main predictive parameter established. This study aimed to identify predictors capable of selecting subgroups with higher risk of tumor progression and adverse overall survival. Design: Patients with PLCT who underwent resection at MDACC between 1997 and 2012 with available clinical information and pathology material were retrospectively identified. Follow up ranged from 13-262 months. Histologic grading of the tumor was evaluated based on the current WHO criteria using mitosis and necrosis. Patients' clinical characteristics were extracted from the medical records. Tumor proliferation index was assessed using Ki67 immunohistochemistry with image-assisted quantitative analysis (Aperio) evaluating both hot spot (hs-Ki67) and mean index (m-Ki67). The primary end point was recurrence free survival (RFS), which was assessed using the Kaplan-Meier method. Univariable and multivariable Cox regression analysis was used to identify predictors for tumor recurrence. Results: One hundred and twenty four patients (M:F=1:1.88, mean age: 52.4) were identified including 101 typical carcinoids (TC) and 23 atypical carcinoids (AC). 74 patients were in pathologic stage I, 17 in stage II, 50 in stage III, and 3 in stage IV. Median follow up was 80.25 months (range, 13-262 months). m-Ki67 and hs-Ki67 ranged from 0.2-8.3 and 0.6-16 in AC, respectively. In TC, the m-Ki67 and hs-Ki67 varied from 0.03-8.7 and 0.1-14.6, respectively. 18 patients developed recurrent/metastatic disease. From univariable analysis, the major risk factors for tumor recurrence were Ki67 proliferation index (hs-Ki67: HR=1.29, p<0.0001; m-Ki67: HR=1.47, p<0.0001) and histologic grade (HR=0.12, p=0.0001). When combined in a multivariable model, Ki67 hot spot index (HR=1.56, p=0.0024) and histologic grade (HR=0.254, p=0.0430) were independent predictors of recurrence after adjustment for age, stage and multifocality. Conclusions: This cohort provides supportive evidence for the use of Ki-67 hot spot index to identify patients with higher risk of tumor recurrence which can help the clinicians plan appropriate therapeutic strategies.
Cell Cycle Progression Score Is a Promising Predictor of Recurrence in Primary Lung Carcinoid Tumors
Neda Kalhor, Junya Fujimoto, Guoping Xu, Ryan Hoff, Placede Tiemeny, Susanne Wagner, Reza J Mehran, Cesar A Moran, Ignacio I Wistuba. MD Anderson Cancer Center, Houston, TX; Myriad Genetics, Inc., Salt Lake City, UT; Dali University, Yunnan, China. Background: The prognosis of patients with primary lung carcinoid tumors (PLCT), including typical carcinoid (TC) and atypical carcinoid (AC), is difficult to predict. The cell cycle progression (CCP) score is a proliferation based expression profile that has been shown to provide significant prognostic information that can be utilized in stratification of NSCLC patients with higher risk of cancer-related death. The purpose of this study was to evaluate CCP score in pulmonary carcinoid tumors resected at a single institution. Design: Formalin-fixed paraffin-embedded surgical tumor samples from 126 patients diagnosed with TC and AC who underwent surgical resection were analyzed for 31 proliferation genes by quantitative PCR. A CCP score was calculated from the mRNA expression levels of these genes. The primary endpoint was recurrence free survival (RFS). Cox proportional hazards regression analysis for the association of clinical variables and CCP score with RFS was performed. Results: The study cohort consisted of 124 patients (M:F=1:1.88, mean age: 52.4) including 101 TC and 23 AC. 74 patients were in pathologic stage I, 17 in stage II, 50 in stage III, and 3 in stage IV. Follow up ranged from 13 to 262 months. 18 patients developed recurrent/metastatic disease (7 TC and 11 AC), and 10 died of cancer-related (4 TC and 6 AC). The CCP score was calculated in 93 patients (79 TC and 14 AC), including 13 recurrences. Histology (HR 0.15, 95%CI 0.05-0.46, p=0.0019), node status (HR 3.45, 95%CI 1.11-10.66), p=0.029), age (HR 1.06, 95%CI 1.01-1.11, p=0.0086), necrosis (HR 7.76, p=0.0047), pathological stage (HR 2.40, p=0.00035 ) and the CCP score (HR 3.15, p=0.00021) were significant predictors of recurrence-free survival in univariate Cox PH models. In a multivariate model, pathological stage (HR 2.74, p=0.016) Background: P16 expression and HPV infections have been strongly linked to cervical and oropharyngeal squamous cell carcinomas (SQCC). However, there is controversy in the involvement of P16 and HPV in lung cancer. Studies have shown an association between both HPV16/18 infected lung tissues and SQCC and have also confirmed a higher HPV infection rate in SQCC. In this study, we examined P16 expression and performed HPV RNA probes on primary NSCLC positive for P16, and correlated levels of P16 with clinical outcomes in NSCLC patients. Design: Primary NSCLC TMAs (0.6 mm in diameter, 3-4 cores per case) were constructed using specimens retrieved from department archives. Included were 75 cases of ADC, 88 cases of SQCC, and 60 tumor-matched normal lung tissues. Immunohistochemistry (IHC) of P16 (clone INK4a/E6H4) was performed. Nuclear staining patterns were scored semi-quantitatively as 0-3+ (negative to strong positive). HPV RNA in situ hybridization (ISH) and HPV subtype detection were then performed. Clinical information was correlated. Results: The overall frequency of high expression of P16 in ADCs and SQCCs was 50.7% and 35.2%, respectively. HPV RNA was detected by ISH in both ADCs and SQCCs with variable P16 stains. HPV16/18 showed a similar detection rate between ADC (23.3%) and SQCC (22.4%); however, HPV31/33 showed higher detection rate of 16.4% in ADC than that of 7.1% in SQCC. In ADCs, patients with p16 positive tumors had smaller tumor size, earlier tumor stage, and longer survival, with a mean survival of 41.1 vs. 28.9 month (P=0.047). In SQCCs, a slightly worse survival for patients with P16 positive tumors (30.1 vs. 37.3 months), It did not reach statistical significance (P=0.382). Conclusions: Our data demonstrates that P16 is aberrantly expressed in a large subset of both ADC and SQCC. A subset of tumors with strong P16 staining were positive for HPV RNA by ISH. Elevated P16 levels appear to be correlated with better prognosis in patients with ADCs, but not of those with SQCCs. These findings suggest that molecular pathways that result in increased P16 levels might play different roles in these different subtypes of NSCLC. Detecting HPV RNA may suggest additional pathways in our understanding of HPV related tumorigenesis. While there has been previous controversy in the role HPV plays in NSCLC, our study shows support that some primary lung cancers are associated with HPV. This association may provide promise as the use of the HPV vaccine becomes more prevalent. Sehui Kim, Moon-Young Kim, Jaemoon Koh, Heounjeong Go, Yoon Kyung Jeon, Doo Hyun Chung. Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea. Background: Immunotherapy targeting the PD-1/PD-L1 pathway has emerged as a promising therapeutic strategy for non-small cell lung cancer. However, mechanism underlying PD-L1 induction in NSCLC cells remains unclear. Epithelial-tomesenchymal transition (EMT) is important for cancer progression and involved in drug resistance and immune evasion. Previously we observed that pleomorphic carcinoma of the lung highly expressed PD-L1. Thus, we investigated the association of PD-L1 expression and EMT phenotype in pulmonary adenocarcinoma (pADC). Design: Immunohistochemical study for PD-L1, E-cadherin, ZEB1, Snail, Slug and vimentin and EGFR mutation analysis were done in 508 cases with pADC. PD-L1 expression was scored from 0 to 3, and cases with score of 2 or 3 were deemed PD-L1-positive. H-score for E-cadherin, ZEB1, Snail, Slug and vimentin expression was estimated. Results: PD-L1 expression was scored 0 in 14.6% (n=74), 1 in 26.6% (n=135), 2 in 50.8% (n=258) and 3 in 8.1% (n=41) of the 508 cases. Comparing PD-L1-negative versus PD-L1-positive group dichotomized, H-scores of SNAIL and vimentin were higher in PD-L1-positive group ( (70 yrs ; 42-87) than in the other MPM group (73 yrs ; 55-97) (p<0,0001). Sixty-seven percent of the myxoid MPM patients were asbestos-exposed, but less than in the control population (p=0,01). Clinically, patients with myxoid MPM presented with less thoracic pain and fatigue (p=0,006 and p=0,04, respectively). By definition, myxoid MPM were characterized microscopically by a diffuse and predominant myxoid stroma and all were of EMM subtype, except 3 cases diagnosed as BMM. At immunohistochemistry, myxoid MPM more frequently expressed CK5-6 and calretinin than the other EMM from the control group (p=0.001 and p=0.003, respectively); there was no striking difference regarding P53, P16 and BAP1 expressions between the two populations. Median overall survival was 26 months for myxoid MPM patients versus 12 for the overall population, and the 3 -year survival rate was twice higher for myxoid MPM than for MME from the control group. Conclusions: Myxoid MPM is a rare histological subtype of MPM, accounting for less than 2% of all MPM; it more frequently affects females, who are less asbestos-exposed. Myxoid MPM is worth to be recognized as it harbors a better prognosis than classical EMM and other MPM. Only cases with surgical follow-up were selected for inclusion in the study. Cytologic diagnosis and subsequent surgical diagnosis were correlated and malignancy risk calculated for each category. Sensitivity and specificity were also calculated. Results: 155 EBUS-FNAs with surgical follow-up were obtained. Comparison of cytologic cases with and without surgical follow-up show no statistical differences in distribution of cytologic diagnoses. Risks of malignancy were: Non-diagnostic 40%, negative for malignancy 24%, atypical 54%, suspicious for malignancy 82% and malignant 87%. Sensitivity and specificity were 81% and 84% respectively for surgically confirmed cytologic diagnoses when indeterminate categories were excluded. Conclusions: The diagnostic categories are associated with increasing risk of malignancy running from negative for malignancy to malignant. The non-diagnostic category has a significant risk of malignancy. While the risk of malignancy for a negative diagnosis is substantial (24%), it is significantly less than that associated with an atypical (54%) or suspicious for malignancy (82%) diagnosis. A suspicious diagnosis carries a risk for malignancy essentially the same as a malignant diagnosis. The categories atypical and suspicious for malignancy appear to have substantially different risks for malignancy (54% vs. 82%). The atypical category has twice the risk of malignancy as a negative for malignancy diagnosis. This risk stratification may be useful for patient management. Background: Invasive mucinous adenocarcinoma (IMA) is characterized by abundant cytoplasmic mucin, lepidic growth pattern, and a tendency for multifocality and occasional bilaterality, presenting as consolidations or nodules radiologically. It is generally presumed that multifocal, particularly pneumonic-type IMA, represents aerogenous spread of a single tumor. However, we have encountered several patients with nodular IMAs, in whom contralateral disease developed after a long time-interval, raising the question of a separate primary tumor. To assess tumor clonality in this setting, we compared molecular profiles of matched bilateral IMAs. Design: A 10-year retrospective search for bilateral IMAs identified 9 patients in whom both lesions had undergone molecular testing. Clinical, radiologic, pathologic features were reviewed. Metastasis from extrapulmonary sites was excluded clinically. Minimum molecular studies included analysis of common KRAS and EGFR mutations. In the majority of cases, mass-spectrometry genotyping for hotspot mutations in additional 6 genes (AKT1, BRAF, ERBB2, MAP2K1, NRAS, PIK3CA) was also performed. Results: 5 patients had metachronous bilateral IMAs with a mean latency of 4.5 yrs (10 mos-8.5 yrs), while the remainder had synchronous bilateral disease at diagnosis. On CT scan, a discrete nodular/mass-forming appearance was more common (13/18, 72%) than a pneumonic-type appearance (5/18, 28%). None of the patients had nodal or distant metastases. In all 9 patients, molecular results in bilateral tumors were identical: KRAS G12V (3 pairs); KRAS G12D (2 pairs); KRAS G12C (1 pair); no mutation (3 pairs). Notably, 2 patients had nodular metachronous IMAs developing with a ≥ 8 yr latency; tumors in both of these patients harbored matching KRAS mutations. Based on the expected mutation frequencies in IMA, the probability of 9 consecutive matched molecular results occurring by chance is 4.1x10 -6 . Conclusions: This is the first study to provide molecular support that bilateral IMAs represent intrapulmonary spread of a single tumor rather than separate primary tumors. They also show that tumor spread can manifest many years after diagnosis, and likely occurs via the aerogenous (large airway) route, as no nodal and distant metastases were observed. This study reinforces the unique biologic and clinical behavior of IMA, and confirms that multifocal IMA is distinct from multifocal, bilateral non-mucinous adenocarcinomas with lepidic pattern, which have been previously shown to generally represent separate primary tumors.
Relationship between PD-L1 Expression and Epithelial Mesenchymal Transition in Adenocarcinoma of the Lung
Histopathologic Findings in the Lungs of Patients Treated with Extracorporeal Membrane Oxygenation
Hee Eun Lee, Eunhee S Yi, Anja C Roden. Mayo Cliinc, Rochester, MN. Background: Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat patients with respiratory and/or cardiac failure, to bridge to lung transplantation or in post-transplantation primary graft dysfunction. The outcome of ECMO is influenced by both the patient's underlying disease and ECMO-related complications. Histopathologic findings in the lungs of patients treated with ECMO have not been systematically studied. Design: Institutional autopsy files were queried for cases with a history of treatment with ECMO. All lung slides from each case were reviewed by a thoracic pathologist blinded to clinical findings. Histologic findings of interstitium, alveoli, airways, pleura, and vasculature were recorded. In some cases Verhoeff-Van Giesson stains (n=8) were obtained. Autopsy reports and medical records were reviewed. Results: Seventy-five patients (38 men) with a median age of 42 years (range, 0-77 years) were included. Histologic findings are summarized in table.
Histologic findings Patients (N=75), N (%)
Pulmonary hemorrhage 47 (62.7)
Acute alveolar hemorrhage 28
Alveolar hemosiderosis 33
Acute lung injury 39 (52.0)
Organizing pneumonia 9
Diffuse alveolar damage 13
Acute or organizing fibrinous pneumonia 7
Acute lung injury, not otherwise specified 1 Results: High Cav-1 expression in tumor cells was observed in 52% (38 out of 73) of squamous cell carcinoma (SQC), and 33% (45/138) of non-squamous cell carcinoma (non-SQC) (P=0.006). While patients with high Cav-1 expression in primary lung non-SQC had a shorter overall survival than the patients with low Cav-1 expression (60.7 months vs. 69.5 months, P=0.083), Cav-1 expression level did not affect the survival diffrences in patients with primary lung SQC (P=0.978). However, the proportion of high Cav-1 expression cases in SQC was increased after BM in both paired and non-paired samples of lung primary and BM (53% vs. 84%, P=0.034; 52% vs. 78%, P=0.020).
In vitro assays revealed that Cav-1 knockdown inhibited invasion and migration of lung cancer cells. Cav-1 knockdown was consistently associated with SNAIL downregulation. This finding was also supported by that SNAIL expression increased along with Cav-1 expression in BM samples of SQC. Conclusions: Cav-1 is believed to play an important role in BM processes of lung cancer, depending on histotypes. The mechanism is possibly linked with SNAIL regulation.
Neuroendocrine Markers Possible Predictive Factors for Survival in Small Cell Lung Carcinoma
James Lee, Zahra Maleki. Johns Hopkins Hospital, Baltimore, MD. Background: Small cell carcinoma comprises ~15-20% of lung carcinomas and usually presents with a hilar mass and disseminated disease. It has a poor prognosis, and most patients are not surgical candidates, so patients are treated with chemotherapy and/or radiation. Few markers are available for prognostication of outcome. Design: From 2008 to 2010, 65 cases of small cell lung cancer were evaluated for synaptophisin and chromogranin expressivity. Expression was categorized as diffusely positive, focal positive, or negative. The time to death from diagnosis was calculated for each category. Results: Out of these specimens, it was determined that when synaptophysin, and chromogranin were each individually positive, the mean time to death from diagnosis was 407 days (mean age 64.6 years, N=22) and 440 days (mean age 61.7 years, N=9),
respectively. This increased to 560 days (mean age 64.6 years, N=10) if both of them together were either diffusely positive or just partially positive. But if synaptophysin was positive and chromogranin was negative, the mean time to death from diagnosis increased to 319 days (mean age 64.3 years, N=8). When synaptophysin and chromogranin were negative, the mean time to death from diagnosis was 237 days (mean age 65.8 years, N=5) and 288 days (mean age 64.9 years, N=14), respectively.
[table1] Conclusions: Loss of synaptophysin and chromogranin expression did not significantly alter the mean age at which small cell lung cancer presents. However, loss of these immunomarkers portended a shorter survival time for the patients involved. Mature teratoma with sarcomatous transformation (n=1)
Chest pain 3 (21) a 1 (100) 1 (100) 0 6 (55)
Shortness of breath
Weight loss 1 (7) 1 ( Background: Early and accurate diagnosis of lung cancer is crucial for effective treatment. This study aimed to identify plasma microRNAs for diagnosis of lung cancer and for further discrimination of small cell lung cancer (SCLC) from non-small cell lung cancer(NSCLC). Design: Plasma microRNA expression was investigated using three independent cohorts including 1132 participants recruited between October 2008 and September 2014 from five medical centers. The subjects were healthy individuals and patients with NSCLC or SCLC. Microarrays were used to screen 723 human microRNAs in 106 plasma samples for candidate selection. Quantitative reverse-transcriptase PCR was applied to evaluate the expression of selected microRNAs. Two logistic regression models were constructed based on a training cohort (n = 565) and then validated using an independent cohort (n = 461). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.
Results: Plasma panel A with six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals (AUC 0.873 and 0.868 for training and validation cohort, respectively). Moreover, plasma panel B with three microRNAs (miR-17, miR190b, and miR-375) demonstrated high diagnostic accuracy in discriminating SCLC from NSCLC (AUC 0.878 and 0.869 for training and validation cohort, respectively).
Conclusions:
We constructed and validated two plasma microRNA panels that have considerable clinical value in diagnosis of lung cancer, and could play an important role in determining optimal treatment strategies based on discrimination between SCLC and NSCLC. where it has been shown to be an independent predictor of recurrence in small lung AD. However, morphologic criteria for STAS and its prognostic impact have not been defined in squamous cell carcinoma. In this study, we investigated whether STAS occurs in resected lung squamous cell carcinoma, and whether it correlates with prognosis. Design: We reviewed a series of surgically resected, solitary lung squamous cell carcinomas (n=445; M/F, 180/265; p-stage I/II/III, 249/131/65). STAS was defined as tumor nests spreading within air spaces in the lung parenchyma beyond the edge of the main tumor. We compared the cumulative incidence of recurrence (CIR) between groups using Gray's test, stratified by pathological stage. The effect of the STAS on recurrence, along with other factors, was evaluated using competing risk analyses.
Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence in Lung Squamous Cell Carcinoma
Results: STAS was observed in 132 cases (30%), with limited (7.2%) and extensive (22.5%) morphologies, respectively. 5-year CIR was significantly higher in patients with STAS-positive (+) tumors compared to patients with STAS-negative (-) tumors (39% versus 26%; p= 0.004). In the lobectomy group (n=376), 5-year CIR was significantly higher in STAS+ than STAS-tumors (39% versus 27%, p=0.014), whereas the difference was not significant in the limited resection group after stratification by pathological stage (44% versus 22%, p=0.242). In multivariate analyses adjusting for smoking pack-years and p-stage, STAS was an independent predictor of recurrence (HR, 1.64; p=0.006) but not of mortality (p=0.3). STAS+ tumors showed significantly higher cumulative incidence of locoregional recurrence among stage I patients (p=0.025), and higher cumulative incidence of distant recurrences among stage II/III patients (p=0.019).
Conclusions: STAS occurs in lung squamous cell carcinoma and is a strong predictor of recurrence, but not overall survival. Further evaluation and validation is needed to determine the prognostic significance and clinical implication of this finding. Results: The mean patient age was 61 years (range: 46-73 years). The lung carcinomas included 16 adenocarcinomas, 2 squamous cell carcinomas, 2 adenosquamous carcinomas, and 1 small cell carcinoma. 13 and 2 patients received anti-PD1 antibodies, pembrolizumab or nivolumab, respectively. 6 patients received MPDL3280A, a monoclonal antibody against PD-L1. The mean PFS was 7.5 months. Across all lung carcinoma histotypes, patients who displayed a DCB had a significantly higher number of NSM (range 2-21) than patients who showed no durable benefit (NDB) [DCB: 13; NDB: 6, p = 0.047]. Patients who had greater than the median number of NSM (9) tended to have longer progression-free survival (10 vs. 4.6 months) than those with 9 or fewer NSM, though this trend did not reach statistical significance (p = 0.087). Expression of PD-L1 in either tumor cells or ICs was not associated with NSM burden (p = 0.85) nor with DCB (p = 0.5).
Non-Synonymous Mutation Burden in Lung Carcinoma
Conclusions:
The NSM burden in lung carcinoma as detected by targeted next generation sequencing is associated with increased duration of response to immune checkpoint inhibitors. In this limited cohort, PD-L1 expression does not predict response to these therapies. We add to growing evidence that increased somatic mutations in carcinomas predict response to immune checkpoint blockade. rarely positive in primary lung cancer. The aim of this study was to determine whether strong and diffuse PAX-8 staining occurs in primary lung carcinoma. To approach the question from another perspective, we reviewed our experience with carcinomas in lung specimens that showed strong and diffuse PAX-8 positivity to determine if any of these subsequently proved to be primary lung tumors. Design: Immunohistochemical staining for PAX-8 (Rabbit polyclonal, 10336-1-AP, Proteintech) was performed on whole-tissue sections from 337 resected primary lung carcinomas (177 adenocarcinomas, 52 carcinoid tumors, 34 large cell neuroendocrine carcinomas, 27 small cell carcinomas, 25 squamous cell carcinomas, 20 sarcomatoid carcinomas, 2 adenosquamous carcinomas). Additionally, we retrospectively reviewed all carcinomas in lung specimens that were read by pulmonary pathologists at our institution as strongly and diffusely positive for PAX-8 (2011-15) . Twenty-seven carcinomas with strong and diffuse PAX-8 staining were identified in lung specimens. In each case, medical records were reviewed to determine if an extrapulmonary primary was documented. Results: PAX-8 was positive in 5/337 (1.5%) primary lung carcinomas. All 5 were large cell neuroendocrine carcinomas (5/34, 15%); staining ranged from weak to moderate, and was seen in 5-10% of tumor cells. All other primary lung carcinomas (332/337) were PAX-8-negative. Review of medical records in the 27 strongly and diffusely PAX8-positive carcinomas in lung specimens revealed a non-pulmonary primary in 26, including kidney (17), endometrium (5), ovary (2), thyroid (1) and pelvis (1), confirmed histologically in 25 cases and radiologically in 1. The site of origin was unclear in 1 patient with a history of thyroid carcinoma. There were no cases of primary lung carcinoma with strong and diffuse PAX-8 positivity. Conclusions: This study, which represents the largest series of PAX-8-stained wholetissue sections of primary lung carcinoma to date, shows that strong and diffuse PAX-8 positivity does not occur in primary lung carcinoma. Focal weak to moderate PAX-8 positivity does occasionally occur in primary lung carcinoma, especially large cell neuroendocrine carcinoma. Strong and diffuse PAX-8 positivity in a carcinoma present in a lung specimen should prompt a search for an extra-pulmonary primary.
Identification of Steroid Receptor Expression in Patients with Usual Interstitial Pneumonia
Mitra Mehrad, Humberto Trejo Bittar, Samuel A Yousem. University of Pittsburgh Medical Center, Pittsburgh, PA. Background: Usual interstitial pneumonia (UIP) is characterized by progressive scarring of the lungs and is associated with high morbidity and mortality despite various therapeutic efforts. Recently, sex steroid receptors have been demonstrated to play an important role in pathological conditions in the lung such as cystic fibrosis, asthma and chronic obstructive pulmonary disease, however, the significance of these receptors is not well understood in patients with UIP. Design: We retrospectively retrieved and reviewed 40 consecutive UIP cases. Diagnosis was made on tissue received from Video-Assisted Thoracoscopic Surgery wedge biopsies or native lung transplantation. Ten cases of unremarkable lung parenchyma from non-UIP patients were used as control cases. Immunohistochemical stains for estrogen receptor alpha (ER-α), progesterone receptor (PR) and androgen receptor (AR) were performed in both groups. Within the UIP cases expression of these receptors was assessed in five areas of each of the following anatomic/pathologic compartments: alveolar and bronchiolar epithelium, blood vessels, mesenchyme including fibroblastic foci, old scar, and uninvolved parenchyma and compared to those in the control cases. Results: The majority (75%) of patients were male. The mean and median age at diagnosis was 62.9 and 62, respectively. All UIP cases (100%) were positive for PR in myofibroblasts in all five examined scarred areas and 34 (85%) showed positivity in smooth muscle cells in at least one scarred region. PR was positive in myocytes of the large-sized vessels within the fibrotic areas in 31 cases (77.5%). In addition, only 11 cases (27.5%) showed PR expression in the uninvolved lung. PR was negative in the fibroblastic foci, endothelium, and alveolar and bronchial epithelium. Among the control cases, PR was expressed in a minority (30%), seen within the fibroblasts of the alveolar septa. All cases and controls were uniformly negative for AR and ER-α, with adequate controls. Conclusions: To our knowledge this is the first study to evaluate the role of steroid receptors in UIP. The increased expression of PR mostly within the established fibrotic areas, indicate that progesterone may have profibrotic effects through its receptors in UIP patients, regardless of gender. Our findings suggest hormonal therapy by targeting PR may be of potential benefit in patients with this devastating disease. Background: Pulmonary Sarcomatoid Carcinoma (SC) includes five different subtypes of a poorly differentiated non-small cell lung carcinoma with an aggressive behavior. The aim of this study was to evaluate the prognostic significance of clinicopathologic and molecular characteristics of SC. Design: Forty-three cases of surgically treated SC, including pleomorphic carcinoma (42/43, 97.7%) and carcinosarcoma (1/43, 2.3%) were selected for the study. Adenocarcinoma was found in 29 (67.4%), squamous cell carcinoma (SCC) in 7 (16.2%), adenosquamous carcinoma in 5 (11.6%) and large cell neuroendocrine carcinoma in 2 (4.6%) cases. Clinical information including gender, age, tumor stage and smoking status were obtained from patient's electronic medical records. Follow-up data with regard to first recurrence and survival were collected through the institutional Network Cancer Registry. Sangers sequencing for EGFR, KRAS, BRAF and PIK3CA and FISH for ALK, ROS1, RET and MET were performed on 27 SC with adenocarcinoma component. FISH for FGFR1 amplification and PIK3CA mutation analysis were performed on SC with SCC component.
KRAS Mutations Are Predictive of Outcome in Patients with
Results:
The majority of patients were male (26/43, 60.4%) and smoker (41/43, 95.3%) with median age of 66 years at diagnosis. The tumors ranged in size from 1.3 to 10 cm (median 4.5 cm). The majority of cases showed angiolymphatic invasion (31/43, 72.1%) and visceral pleural invasion was present in 20 cases (46.5%). The most common genetic alteration in SC with adenocarcinoma component was codon 12 KRAS mutation (16/27, 59.2%). EGFR mutations were identified in 2 (2/27, 7.4%) and MET amplification in one (3.7%) case. No FGFR1 amplification or PIK3CA mutation were identified. Mean follow-up duration was 29 months. Overall, 16 of 25 (64%) patients died within 1 to 34 months (mean 11.2) after diagnosis, and 18 were alive as of 5 to 118 months (mean 39) after diagnosis. Five-year overall survival (OS) was 12.5% for the whole population. At univariate analysis, KRAS (p =0.017) mutations were associated with significantly decreased survival (mean survival of 24.9 versus 32.6 months in wild-type KRAS). There was no sufficient data to reliably assess prognostic significance of EGFR mutations and MET amplification. No correlation was found between clinicopathologic characteristics, patient demographics and outcome. Conclusions: Our data suggests that KRAS codon 12 mutations are the most common genetic alteration in SC and the most important predictor of aggressive behavior in SC with adenocarcinoma component.
Next Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Testing Yields More Actionable Results
Mitra Mehrad, Marina Nikiforova, Humberto Trejo Bittar, Sanja Dacic. University of Pittsburgh Medical Center, Pittsburgh, PA. Background: The current guidelines recommend testing for EGFR mutations and ALK rearrangements in all patients with advanced-stage lung adenocarcinoma. Additional gene targets have been proposed, and it is unclear if the patients would benefit from broader gene panel testing. In our institution, metastatic adenocarcinomas are subjected to a reflex testing for 8-gene panel composed of Sangers sequencing (SS) for EGFR, KRAS, PIK3CA and BRAF and FISH for ALK, ROS1, MET and RET. At the oncologist request, a subset of wild-type tumors can be subjected to a 50-gene mutation panel by Ion Torrent AmpliSeq. The aim of this study was to determine whether a large gene panel testing by NGS would improve the detection of actionable genetic abnormalities. Design: A total of 120 NCLCs were subjected to NGS, of which 35 cases were wild-type by SS and were subjected to sequencing by Ion Torrent. Cases included: 26 (74.3%) adenocarcinoma, 5 (14.2%) large cell neuroendocrine carcinoma and 4 (11.5%) poorly differentiated non-small cell carcinoma.
Results: Among the 35 cases, NGS detected 9 actionable variants (9/35, 25.7%), occurring in the following genes: ERBB2 (3, 8.5%), FBXW7 (2, 5.7%), BRAF G469A (1, 2.8%), RET (1, 2.8%), MET (1, 2.8%)and PTEN (1, 2.8%). In addition, NGS detected codon 12 KRAS mutation in one case that was missed by Sangers sequencing. (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Immunohistochemistry for CD34 and STAT6 was performed. Follow-up data was collected from clinical records. Kaplan-Meier analysis was used to estimate overall survival (OS). Tumors were risk stratified using the following proposed schemes: -Demicco et al: Includes age, size and mitoses, and stratifies patients to low, moderate, or high risk.
-DePerrot staging system: Includes pedunculation and "histologic features of malignancy" (cellularity, pleomorphism, mitoses, necrosis, stromal/vascular invasion), dividing patients into 5 stages (0-4).
-Tapias et al: Includes pedunculation, site (parietal or visceral), size, cellularity, necrosis, hemorrhage, and mitoses, dividing patients into low and high risk. Results: Patients included 51 females and 33 males with a median age of 64 years (26-87). Mean follow up was 5.3 years (0-21). Immunostains were performed in 76 cases: all were STAT6 positive, while 74 (93%) were CD34 positive. Adverse outcomes occurred in 4 patients (5%, 3 recurrences, 2 metastases), with 2 deaths from disease and 11 deaths from any cause. The 4 patients with progressive disease were all high risk by Tapias method; and 3 were high and 1 moderate by Demicco system; using DePerrot staging, 1 was stage 2, 2 stage 3, and 1 stage 4. Significant adverse predictors of OS included male gender, extrapulmonary location, severe atypia, necrosis, age, size, and mitoses; pedunculation was not significant. The ability of the DePerrot system to predict OS did not reach significance (p=0.08), while both Tapias and Demicco models performed well in predicting OS (p= 0.003 and 0.006 respectively). Conclusions: The scoring systems proposed by Tapias and Demicco were both predictive of OS, while DePerrot stage did not significantly correlate with outcome. The Demicco system has the advantage of simplicity, and thus may be the best system to apply in general practice. Background: Introduction of next generation sequencing (NGS) has been a great advance for molecular testing of lung cancers, however, since patients with advanced disease often need rapid results to initiate therapy it has also presented some challenges. Design: We analyzed 1 year of biopsies managed by the thoracic pathology service beginning September 2014 using NGS using the Illumina HiSeq custom capture based platform analyzing mutations and copy number of 341 genes. Due to the 4 week delay for NGS results, to obtain more rapid results for key actionable mutations we test by IHC using mutation specific antibodies for ALK (D5F3, Ventana) and EGFR L858R (43B2, Cell Signaling) and Sanger sequencing (SS) for EGFR exon 19, EGFR exon 20 and ERBB2/HER2 exon 20 deletions. We focused on discrepant results in the 288 cases studied by NGS versus IHC and ALK FISH. Results: In the 288 cases examined for NGS, 234 were AD, 31 squamous, 5 small cell, 5 LCNEC including one combined with AD, 10 nonsmall cell, 2 pleomorphic and 1 adenosquamous carcinoma. EGFR mutations were found in L858R (NGS) and Exon 19 deletions (SS) in 27 (9%) and 39 (14%) of cases (all with AD) respectively. Other therapeutically relevant mutations found included KRAS:89 (31%). BRAF: 11 (4%), ERBB2/HER2:3 (1%), RB: 2 (0.7%), and AKT: 1 (0.3%). ROS1 fusion was found in 1 (0.3%). Of 618 cases stained for EGFR L858R, 45 were positive (7.3%, all ADC) and 9 were equivocal (1.5%). In cases with NGS, in all 25 EGFR L858R mutant cases IHC showed either positive (21, 88%) or equivocal (3, 12%) staining. However, IHC was positive in 3 of 64 (5%) cases without mutation. Of false-positive cases two showed ERBB2 amplification (fold change of 8 and 19) and a third showed an EGFR exon 19 deletion. Positive HER2 IHC was seen in one of the ERBB2 amplified cases. Of 630 cases stained for ALK, 18 were positive (all AD, 2.9%) and 5 were equivocal. All 8 cases positive for ALK IHC and one of 4 equivocal cases showed ALK rearrangement by NGS and/or FISH. In one case confirmed by NGS, ALK IHC was negative.
Lessons Learned from Next Generation Sequencing in Use of Immunohistochemistry (IHC) for EGFR L858R and ALK in Lung Cancer
Conclusions: Our data suggests false positive IHC for EGFR L858R can rarely occur in the setting of ERBB2/HER2 amplification and EGFR Exon 19 deletion. While IHC for EGFR mutation is used for therapeutic decisions, it remains useful to perform molecular testing using NGS. Further study is needed to see if IHC for HER2 may be a useful marker for ERRB2/HER2 amplification as a cause of false positive EGFR L858R staining.
Venous Infarcts and Pathologic Changes Mimicking Pulmonary Venoocclusive Disease Caused by Pulmonary Vein Obstruction outside the Lungs
Sanjay Mukhopadhyay, Andrea V Arrossi, Carol Farver. Cleveland Clinic, Cleveland, OH. Background: Pulmonary venoocclusive disease (PVOD) is a rare vasculopathy caused by occlusion of intrapulmonary venules. We present a series of cases in which pathologic changes similar to PVOD were caused by pulmonary vein obstruction outside the lungs. Design: We identified 4 surgical lung biopsies in which venous infarcts and other PVOD-like changes were identified in patients with clinical evidence of pulmonary vein obstruction outside the lung. Clinical, radiologic and pathologic findings in these cases were reviewed. Results: All 4 patients were young men (25-39 years). Presenting symptoms included cough (3/4), chest pain (3/4), dyspnea (2/4) and hemoptysis (2/4). Chest CT findings in the lung parenchyma included unilateral nodular densities or opacities in all 4 cases, which progressed to consolidation in 1 and were associated with interstitial changes in 1. The clinico-radiologic differential diagnosis included malignancy, infection, septic emboli and granulomatosis with polyangiitis. Infarction was suspected clinically in only 1 case. Obstruction of the pulmonary vein was noted radiologically in all 4 cases. The cause of obstruction was fibrosing mediastinitis in 2 cases (with rare Histoplasma yeasts seen on biopsy in 1, typical radiologic features in the other), bronchogenic cyst in 1 (confirmed pathologically) and pulmonary vein stenosis following radiofrequency ablation for atrial fibrillation in 1 (CT angiogram performed after lung biopsy showed findings suspicious for pulmonary vein obstruction, as well as pulmonary emboli). Pathologic findings in all 4 cases included hemorrhagic subpleural or paraseptal ("venous") infarcts surrounded by a rim of fibroblasts mimicking organizing pneumonia, mild interstitial thickening by congested capillaries, and variable numbers of hemosiderin-laden macrophages within airspaces. The infarcts contained hematoidin in 3 cases. Infarction of interlobular septa was noted in 2. The pleura was thickened by prominent granulation tissue in 3 cases and contained congested vessels in the fourth. All 4 cases showed pulmonary vascular changes secondary to venous obstruction, including congestion and dilatation of veins and capillaries, and intimal fibrosis and medial hypertrophy of arteries. These changes were severe enough to merit consideration of a vascular malformation in 1 case and pulmonary hypertension in 2 cases. Conclusions: Obstruction of pulmonary veins outside the lungs can cause venous infarcts, interstitial changes and secondary vascular abnormalities that can mimic PVOD and other vasculopathies. Background: Diffuse large B-cell lymphoma and related entities are the commonest type of non-Hodgkin lymphomas. However primary involvement of respiratory system by aggressive B-cell lymphoma (ABL) is extremely uncommon, diagnostically challenging and poorly studied. Design: 760 consult cases that were diagnosed as ABL including Burkitt lymphoma (BL), B-cell lymphoma unclassifiable, including double hit lymphomas (DHL), and diffuse large B-cell lymphoma (DLBCL) were evaluated using an extensive panel of immunohistochemical stains (CD20, CD3, CD5, CD10, Cyclin D1, BCL6, BCL2, EBER, Ki-67, CD30) and a panel of FISH studies (including MYC, IgH/BCL2 and BCL6). Forty-four (5%) cases were identified in the respiratory tract; 43% were located in nasopharynx. Results: The majority of cases were DLBCL (37/44; 84%), with two cases of BL (4%), three lymphomatoid granulomatosis (6%), one DHL (2%) and one plasmablastic lymphoma (2%) identified. MYC translocation was only identified in BL and DHL. Compared to a large group of lymphoma in other organs, respiratory tract lymphomas were more often positive for EBV (25% vs. 8%) and were of non-germinal center origin (~67%) by both Hans and tally classifiers (compared to 60% germinal center origin in other organs). Conclusions: Our series shows that aggressive lymphomas in respiratory tract show heterogeneity of immunophenotype and genetics. Also the cell of origin in respiratory tract lymphoma differs from the large group of lymphoma in other organs (33% GC vs 60% GC).
Diagnostic Utility of Orthopedia Homeobox (OTP) in Pulmonary Carcinoid Tumor
Daisuke Nonaka, George Papaxoinis, Was Mansoor. The Christie Hospital, Manchester, United Kingdom; The University of Manchester, Manchester, United Kingdom. Background: Recently OTP (Orthopedia Homeobox) has been described as a prognostic marker for pulmonary carcinoid tumors, however, little is known about the function and distribution pattern of this transcription factor in normal organs/tissues and tumors, herein, OTP immunohistochemistry expression was investigated on a number of tumors, with special interest in pulmonary and non-pulmonary neuroendocrine tumors and high grade neuroendocrine carcinomas.
Design:
cell), 102 non-pulmonary neuroendocrine tumors (52 G1/G2 neuroendocrine tumors, 12 small cell carcinomas, 30 Merkel cell carcinomas, 8 large cell neuroendocrine carcinomas), 150 endocrine tumors (73 thyroid, 7 parathyroid, 27 adrenocortical, 20 pheochromocytomas, 23 paragangliomas), 279 adenocarcinomas and 88 squamous cell carcinomas of various organs, including those of lung, other types of carcinomas, and melanomas. Additionally, normal tissues from various organs except for CNS were studied. The extent of nuclear staining was graded as follows: 1+, 1-25%; 2+, 25-50%; 3+, 50-75%; 4+, ≥ 75%. Results: OTP expression was seen in 81% of lung carcinoid tumors (88% in typical, 49% in atypical), and 4+ staining was seen in 75% of the tumors. Among other tumors, 4 small cell carcinomas showed focal expression (1+ in 2 pulmonary, 1+ and 2+ in 2 bladder tumors), but all other tumors were completely negative. Overall the sensitivity and specificity of OTP was 80.9% and 99.7%, respectively. Notably, all TTF1 positive tumors were positive for OTP with 3+ or 4+ reaction, but none of OTP negative tumors were positive for TTF1. OTP expression was not seen in any normal tissues/organs. OTP was also negative in neuroendocrine cells of the normal bronchus/bronchiole, however, OTP was strongly expressed in neuroendocrine hyperplasia, including reactive and preneoplastic hyperplasia (DIPNECH). Conclusions: OTP may serve as a useful diagnostic marker for lung carcinoid tumors, particularly in the setting where the differential diagnosis is lung carcinoid vs. small cell carcinoma, or where lung origin needs to be confirmed in metastatic well differentiated neuroendocrine tumors. Absence of nuclear BAP1 staining by immunohistochemistry (IHC) has likewise been reported in up to 60% of PDMM, with good correlation to BAP1 genetic alterations, and has therefore been proposed as a diagnostic marker. Systematic correlation between BAP1 IHC and genetic alterations to include sequence alterations, copy number variation (CNV), and rearrangements, however, is lacking. The aim of this study is to correlate BAP1 IHC with gene-level changes in PDMM to support its use as a clinical tool. Design: Included were 78 PDMM and one peritoneal mesothelioma with available next generation sequencing (NGS) data collected between 2013-2015. Targeted hybrid capture NGS for 309 cancer-related genes including BAP1 was performed for detection of single nucleotide variants (SNVs), indels, CNVs, and rearrangements. BAP1 (Santa Cruz C4 antibody; dilution 1:50) IHC was performed on 4 micron formalin-fixed paraffin embedded tissue sections following pressure cooker antigen retrieval, and scored as positive or negative. Results: The study included 47 (59%) epithelioid, 6 (8%) sarcomatoid and 26 (33%) biphasic PDMM. Overall, 54 (68%) tumors had BAP1 alterations, including 2 (2.5%) homozygous deletions (2DEL), 1 (1%) 142 base pair deletion, 2 (2.5%) rearrangements, 6 (8%) loss-of-function SNV or indels, 18 (23%) biallelic alterations, 8 (10%) SNV of unknown significance (VUS), and 9 (11%) heterozygous deletions (1DEL). Of these 54 cases, 48 (89%) showed loss of nuclear BAP1 IHC expression. 6 cases with genetic alterations demonstrated weak/heterogeneous BAP1 nuclear expression, of which 3 harbored 1DEL and 3 harbored VUS. No WT cases had BAP1 loss. Excluding 1DEL and VUS as alterations of unknown functional significance, loss of nuclear BAP1 expression yielded a sensitivity of 100%, specificity of 72% positive predictive value of 75% and negative predictive value of 100%for deleterious BAP1 alterations. Conclusions: Complete loss of BAP1 IHC expression is highly sensitive for loss-offunction BAP1 genomic alterations in PDMM . A minority of cases showed BAP1 loss in the absence of confirmed functional alterations, which may reflect limitations of IHC, limitations of NGS, or additional mechanisms of BAP1 deregulation. In summary, our results support the use of BAP1 IHC as a diagnostic tool and potential screening assay for significant BAP1 genomic alterations.
Clinico-Pathologic Characteristics of Primary Lung Carcinoma with Hepatoid Differentiation
Prodipto Pal, Lucian Chirieac. Brigham and Women's Hospital, Boston, MA. Background: Primary lung carcinoma with hepatoid morphology and differentiation is an exceedingly rare group of aggressive tumors. Distinction from primary hepatocellular carcinomas with hepatoid morphology is critical as there is direct impact in clinical and therapeutic decisions. In this study, we describe the clinico-pathologic characteristics and outcome in a series of 9 patients with primary lung carcinoma with hepatoid differentiation and characterize the histopathological parameters that may aid in diagnosis of these tumors. Design: A search of the surgical pathology database from Brigham and Women's Hospital between January 2005 and August 2015 identified 7 women (median age, 58 yrs, range 45-78 years) and 2 men (median age, 44.5 years, range 42-47 years) with a diagnosis of lung carcinoma with hepatoid differentiation. Clinical presentation, staging data and survival were obtained from review of clinical charts. All patients included in this study had no evidence of primary liver tumors. Immunohistochemical studies were available for TTF-1, CK7, hepatocytic markers (Hep Par-1, arginase-1, glypican 3) and polyclonal CEA (pCEA) in the majority of cases. Results: Eight of our patients had documented smoking history (range, <1 pack year to 100 pack years). All the tumors had hepatoid cytomorphology with predominantly solid Background: ROS1 gene rearrangements occur in 1-2% of lung adenocarcinomas and predict response to crizotinib therapy. The optimal approach to ROS1 translocation detection has not yet been established, however many labs depend on fluorescence in situ hybridization (FISH). FISH is costly and time consuming; immunohistochemistry (IHC) for ROS1 protein is a promising screening tool, although there is limited published data on its use in routine clinical practice. In this study we examine the performance of ROS1 IHC in practice including its correlation with FISH and next generation sequencing (NGS). Design: Upon clinical request, ROS1 IHC was carried out using clone D4D6 (Cell Signaling Technology) on 4 micron sections and reported as negative, equivocal (weak/ focal staining) or positive (moderate to strong, diffuse). All IHC positive and equivocal cases were analyzed by FISH; specimens from patients enrolled in the Lung Cancer Mutation Consortium study underwent FISH testing regardless of IHC result. FISH testing was carried out using commercially available ROS1 breakapart probes (Kreatech) using published procedures. Targeted hybrid capture next generation sequencing (NGS) for 309 cancer-related genes was performed for detection of mutations, indels, copy number variants (CNV), and rearrangements in a subset of cases. Results: From July 2013 to September 2015, ROS1 IHC was performed on 943 lung tumors. Positive ROS1 protein expression was detected in 19 cases (2%). Of these, FISH confirmed a rearrangement in 8, was negative in 7, and gave no result in 4. Equivocal ROS1 staining was reported in 40 cases (4%); FISH was successful in 27 equivocal cases and all were negative for rearrangement. Of 69 cases that were IHC negative but for which FISH was requested, ROS1 FISH was successful in 58 cases and all were negative for rearrangement. NGS results were obtained in cases with equivocal (n=2) and positive (n=2) ROS1 IHC staining that failed FISH; both positive cases contained a CD74-ROS1 fusion. No ROS1 fusions were detected by NGS in the equivocal cases. Conclusions: ROS1 protein detected as moderate to strong and diffuse staining by IHC is 100% sensitive and 93% specific for a rearrangement by FISH or NGS. Tumors with negative or equivocal ROS1 expression are consistently negative for ROS1 rearrangement. ROS1 IHC is a reliable screening tool in clinical practice; reflexive confirmation using FISH or molecular techniques should be restricted to tumors with moderate to strong and diffuse expression.
Molecular Characterization of Invasive Mucinous Adenocarcinomas of the Lung
Kyung Park, Shivakumar Subramaniyam, Jose Jessurun, Helen Fernandes, Navneet Narula. NYPH-WCMC, NYC, NY. Background: Invasive mucinous adenocarcinomas of the lung (IMA) are clinically and genetically distinct from non-mucinous subtypes. Recent studies suggest that IMA share some molecular signatures with colorectal and pancreatobiliary carcinomas. In this study, we investigated the mismatch repair profiles and microsatellite instability (MSI) status of these tumors. In addition, we attempted to correlate the presence of KRAS mutations with the tumor type. Design: The cohort consisted of 60 lung resection specimens collected from 2001 to 2013 at New York Presbyterian Hospital-Cornell Campus. Tumors were classified based on the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification. A tissue microarray (TMA) composed of two representative cores of each tumor was constructed from formalin-fixed paraffin-embedded (FFPE) tissue blocks. Immunohistochemistry (IHC) using antibodies against MLH1, PMS2, MSH2, and MSH6 was performed. Thirteen cases with equivocal or negative immunostaining were subjected to PCRbased MSI testing. KRAS mutation status of the tumor tissue was determined by Sanger sequencing following DNA extraction from FFPE tissue. Results: Sixty patients with IMA including 22 (37 %) males and 38 (63%) females with a median age at diagnosis of 71.5 years were analyzed. The majority of patients had lower T stage: 30 (50%) with T1; 15 (25%) with T2; 11(18%) with T3; 4 (7%) with T4. Six patients had lymph node metastases and one patient had M1 disease at the time of resection. 38/57 (67%) had a history of smoking and 19 (33%) were non-smokers. The entire cohort was microsatellite stable with functional mismatch repair genes. 17 of the 26 (65%) cases interrogated, harbored the following variants in the KRAS gene: 4 patients with G12C, 8 patients with G12V, 4 patients with G12D, and 1 patient with both G12V and G12D. 75% of the KRAS variants were G→ T transversions and 25% were G→A transition mutations. Patients with KRAS variants had higher tumor stage (T3 or T4) compared to those without mutations; 29% and 0%, respectively. There was one BRAF, one EGFR and 2 ALK translocations that were detected in the cohort.
Conclusions: This study illustrates that IMA are microsatellite stable with a high prevalence (65%) of KRAS mutations. Transversions are more frequent than transition mutations. Additional molecular analyses would help in the further characterization of this subset of tumors.
Neoadjuvant Treatment Response Predicts Survival in Non-Small Cell Lung Cancer Resections
Adina Paulk, Alexander A Berrebi, Allen P Burke. University of Maryland Medical Center, Baltimore, MD. Background: Neoadjuvant chemotherapy or radiation is often used in Stage III nonsmall cell lung carcinoma prior to surgical resection. Few studies have investigated the predictive potential of percent treatment response in lung cancer resections; no study has investigated the effect of neoadjuvant therapy on metastatic disease in lymph nodes. Design: We retrospectively reviewed 61 resections for non-small cell lung cancer following neoadjuvant therapy performed between 2003-2012 . Specimens were evaluated for percentage of residual tumor. Electronic medical records were utilized to track length of survival from time of resection, and disease specific survival. Kaplanmeier survival curves were generated for tumors with 100% response and <100% treatment response. Results: The M:F ratio was 0.9 with mean age of 58. Percentage of treatment response ranged from 20-100%. 40/61 (63%) of specimens showed 100% treatment response in the primary tumor. Of these, 14 patients were deceased (35%), with 3 dead of progressive disease. Of the 21 (34%) patients with < 100% residual tumor, 13 (42%) were deceased with 6 dead of progressive disease. Kaplan-meier survival analysis showed superior survival for patients with 100% treatment response compared to all patients with <100% response (p=.04) (see figure 1) . 59 patients underwent lymph node dissection. Residual metastatic tumor was present in lymph nodes in 5 patients (8%); all but 1 of these patients also had incomplete treatment response in the primary tumor.
Conclusions:
Complete treatment response is associated with a superior prognosis. Residual lymph node disease was uncommon and seen most often in cases where there was incomplete treatment response in the tumor. 
Dissecting Intra-Tumor Heterogeneity of Lung Adenocarcinoma
Background: While lung adenocarcinoma (ADC) is morphologically heterogeneous, little is known about intra-tumor gene mutation heterogeneity (ITH).
Design: Twenty ADC nodules mutated for EGFR (5 cases) or KRAS (5 cases), with ALK translocation (5 cases) or wild type (WT) for these alterations (5 cases) were subjected to unsupervised targeted next generation sequencing in diversely patterned tumor regions by using the 50-gene Ion AmpliSeq Cancer Hotspot Panel v.2 running on the Ion-Torrent TM Personal Genome Machine platform (Life Technologies-Thermo Fisher Scientific, USA). Two or more gene mutations per single tumor fulfilled criteria for ITH. Results: A total of 84 tumor regions with diverse architecture accounted for 71 gene mutations and 34 WT profiles. ITH was observed in 3 EGFR, 3 KRAS and 3 ALK tumors, with the finding of 5, 6 and 9 additional mutations, respectively. EGFR mutations were found in 21/22 (95%) and KRAS mutations in 18/22 (82%) tumor regions, suggesting earlier appearance and driver role (dominant or trunk mutations), but with a temporally later emergence of KRAS compared to EGFR mutations. There were also branching mutations (EZH2, PIK3CA and TP53) occurring in two or more regions, which supported some driver role for them in the development of individual tumor nodules. In turn, ABL1, ALK, BRAF, HER2, KDR, LKB1, PTEN, MET, SMAD4, SMARCB1 and SRC were private/passenger/hitchhiker mutations confined to single tumor spots of individual lesions, which were likely to be involved in the growth of single tumor sub-clones (and then temporally delayed) but potentially responsible for unexpected secondary resistance upon therapy. EGFR was mutated in low-grade (lepidic, papillary and acinar) tumor regions, while KRAS or ALK translocation-associated mutations occurred in high-grade (solid, acinar-cribriform, micropapillary and high-grade fetal) tumor spots (p<0.0001). Branching mutation patients ran a worse clinical course (p=0.040). Conclusions: ITH accounted for a spatial/temporal hierarchy of dominant, branching and private mutations, suggesting diverse clonal evolution with potential implications for patient prognosis or secondary resistance development upon therapy.
Proliferation Activity Evaluation by Ki-67 Labeling Index in Paired Biopsy Samples and Surgical Specimens of Pulmonary Neuroendocrine Tumors: A Methodological Approach for Clinical Purposes
Giuseppe Pelosi, Mara Cossa, Alessandra Fabbri, Barbara Valeri, Angelica Sonzogni, Ugo Pastorino. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy. Background: Although classification of lung neuroendocrine tumors (NET) is based on the histologic assessment of surgical specimens (SS), little is known about the use of proliferation-related indexes in biopsy samples (BS) of these tumors for clinical purposes. Design: Twenty-one lung NET outlined according to 2015 WHO classification were assessed for Ki-67 antigen by immunohistochemistry, mitoses and necrosis in paired BS and corresponding SS. In each tumor case, Ki-67 was counted manually as the percentage of positive tumor cells by scanning hot spot areas (HAS) according to four different methods: 500 cells; one 40x-high power field (diameter 0.55 mm); 2000 cells; and 2 mm 2 or the entire tumor fragment(s) if this criterion was not fulfilled in BS. Mitoses were counted in 2 mm 2 or the entire fragment(s) in BS, whereas necrosis was dichotomized as absent or present (whatever extent). Statistical analysis was according to Mann-Whytney and Kruskal-Wallis tests. Results: There were 9 typical carcinoids (TC), 6 atypical carcinoids (AC), 2 large-cell neuroendocrine carcinomas (LCNEC) and 4 small cell carcinomas (SCC), in 13 females and 9 males. Twelve of them were in stage I (6 TC, 3 AC, 1 LCNEC and 2 SCC), 4 in stage II (2 TC, 1 AC and 1 SCC), and 5 in stage III (1 TC, 2 AC, 1 LCNEC and 1 SCC). Pairwise comparison of BS and SS did not show significant differences in Ki-67 LI when dealing with 500 cells (p=0.429), the entire 40x field (p=0.689), 2000 cells (p=0.689) and 2 mm 2 (p=0.936). Likewise, no significant differences in Ki-67 LI were observed when contrasting the four different categories in both BS and SS (p=0.988) or stratifying for histology in either type of material (p=0.174 to p=0.985). However, AC tended to show higher Ki-67 LI in SS than in BS, although differences were not significant (p=0.174) likely due to heterogeneous distribution of proliferating cells within individual tumors. In turn, mitoses were more easily identifiable in SS than in BS (p=0.003), whereas no differences were observed in the prevalence of necrosis (p=0.733). Conclusions: Ki-67 LI in BS was as accurate as SS according to all the four different methods under evaluation. Ki-67 LI was more versatile but not more time consuming than mitoses and thus could have potential relevance to prognosis and tumor grading when assessing lung NET in BS.
Salivary Gland-Type Primary Tumors of the Lung: A Systematic Review
Emilian Racila, Erin Maxfield. University of Minnesota, Minneapolis, MN. Background: Primary salivary gland tumors of the lung are rare entities that are difficult to recognize mainly due to the limited experience most pathologists have in diagnosing these neoplasms in the lung. There are few published reports addressing the diagnostic characteristics of these tumors. We sought to determine the most important epidemiologic, morphologic and immunophenotypic features of these lesions. Design: We identified 62 patients from our facility who were diagnosed with lung adenoid cystic carcinoma (ACC) or mucoepidermoid carcinoma (MEC) since 1996 to present. All inside cases were reviewed and characterized based on their morphologic and immunophenotypic characteristics. In addition we reviewed 19 published single case reports and 8 retrospective multiple case studies from domestic and international sources spanning 1988 to present. Results: Our study population comprised 50 patients with ACC and 12 patients with MEC. In the ACC group, there were 22 (44%) primary lung tumors and 28 (56%) metastatic ACC to the lung. The primary lung ACC comprised of 14 females (28%) with a mean age of 47.4 years and 8 males (16%) with the mean age of 56.8 years. The overall mean age at the time of primary lung ACC diagnosis was 50.8 years. Metastatic ACC to the lung included 15 females (30%) with a mean age of 46.6 years and 13 males (26%) with mean age of 48.7 years. The overall mean age at the time of ACC diagnosis was 47.6 years. In the MEC group, there were 8 (67%) primary lung tumors and 4 (33%) metastatic MEC to the lung. The primary lung MEC comprised of 3 females (25%) with a mean age of 57 years and 5 males (42%) with the mean age of 31 years. The overall mean age at the time of lung primary MEC diagnosis was 40.8 years. Metastatic MEC included 4 patients (33%), all males, with a mean age of 69.8 years. There were no significant histologic or immunophenotypic differences between primary and metastatic ACC or MEC of the lung. Conclusions: Although there are no significant differences in the histologic grade or immunophenotype of the tumors, we found epidemiologic differences related to gender and age at time of diagnosis between primary and metastatic ACC and MEC of the lung. Clinical outcome analysis for both lung ACC and MEC is currently in progress. A comprehensive interpretation of important morphologic and immunophenotypic features for diagnosis of primary lung ACC and MEC is presented. Design: All surgical resection cases (excluding biopsies/referrals) with a diagnosis of C-HNLC, surgically resected at M.D. Anderson Cancer Center were retrieved by searching the pathology database. H&E slides and accompanying immunohistochemistry slides were reviewed. Results: A total of 11 cases were identified. Pre-operative diagnosis of C-HNLC with both components was established in only 1 of 11 patients with all other FNA/ biopsies consisting of either adenocarcinoma or neuroendocrine carcinoma component alone. The histology of combined tumors is listed in table1.
Histology of C-HNLCs
Number of cases (11) Adenocarcinoma+LCNEC 5 Adenocarcinoma+SCLC 3
Squamous cell carcinoma+SCLC 1 LCNEC+SCLC 2
The LCNEC component was dominant in 5 cases, adenocarcinoma in 4 cases, SCLC in 1 case; while equal proportions of both adenocarcinoma and LCNEC was noted in 1 case. 4 of 11 cases had metastatic nodal disease (all 4 were N1), with metastatic deposit demonstrating adenocarcinoma histology in 2 cases and SCLC in the other two. 3 patients had Stage I (IA: 2, IB:1), 6 patients had Stage II (IIA:4, IIB:2), and 2 patients had Stage III (IIIA:2) disease. Upon follow-up, 7 patients had no evidence of disease over a follow-up period ranging from 1-32 months; while 4 patients had disease progression due to local recurrence (or) distant metastasis over a follow-up period ranging from 18-58 months. In patients that had disease progression, the time interval for recurrence/ metastasis ranged from 2-6 months.
Conclusions: There was a major discordance in the diagnoses between biopsies and resections, which translates to a potential impact on the optimal management of these tumors. Most frequent histologic combination in the primary tumor were LCNEC and adenocarcinoma, while the metastatic tumor had either SCLC or adenocarcinoma alone. There was no correlation between the histology/proportion of the dominant component in the primary tumor and metastatic tumor. Conclusions: Low expression of SerpinB2 in lung adenocarcinomas was associated with reduced LCSS and was an independent prognostic factor in multivariate analysis in our cohort. In contrast to previous findings by others, we did not find an impact of Neuroserpin and L1CAM on survival. Low expression of SerpinB2 could be a biomarker for prognosis in lung adenocarcinomas and should be studied in other cohorts. 
Evaluation of Genomic Complexity in
Conclusions:
The frequency of mutations in major oncogenic drivers does not vary significantly between T1 and stage IV ACA, consistent with the observation that EGFR and KRAS mutations are early events in lung tumorigenesis. However, advanced stage tumors are significantly more likely to harbor TP53 mutations and higher levels of CNV consistent with genomic instability, suggesting that these are later events in lung ACA progression. Conclusions: LCNEC is a heterogenous category, representing a histologic convergence of tumors genomically and clinicopathologically related to SCLC, NSCLC and rarely highly proliferative carcinoids. Our findings suggest that recognition of these molecular subsets may inform the classification and management of LCNEC patients. 67% pts were completely resected. Fibrosis was the most common histologic finding in post-NAT thymomas (T) (80% of cases) and thymic carcinomas (TCa) (100%); necrosis was uncommon in T (13%) in contrast to TCa (53%) (p=0.008). Agreement for TRG by 3 reviewers was good (Krippendorff α, 0.838). By imaging (N=24), partial response and larger reduction in tumor diameter and volume were associated with lower TRG (p=0.0093, p=0.0042, p=0.0021, respectively) and less % viable tumor (p=0.0041, p=0.0034, 0.0019). TRG and radiologic change in tumor diameter correlated (Spearman correlation coefficient, 0.60). Radiologic change in tumor diameter and volume reasonably predicted pathologic TRG of 3-5 vs TRG 1,2 (AUC 0.74, 0.71, respectively). Conclusions: Our proposed histologic TRG for TET appears easy and reproducible and correlates with radiologic response. Radiologic response is useful to predict pathologic response.
Comprehensive Analysis of EGFR Mutation Status in Lung Adenocarcinoma Combined with Nonadenocarcinoma Component
Mee Sook Roh, Hyoun Wook Lee. Dong-A University College of Medicine, Busan, Korea; Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea. Background: Lung adenocarcinomas (ADs) are found to be composed of a mixture of nonadenocarcinoma (non-AD) components. We analyzed EGFR mutation at each component in AD combined with non-AD component to investigate the relationship between EGFR mutation status and the histologic type and volume of non-AD component.
Design:
We analyzed 39 Korean patients with surgically resected lung cancer (19 adenosquamous carcinoma (ADSQ), 9 neuroendocrine carcinoma combined with AD (NE-AD; 3 small cell lung carcinoma combined with AD (SCLC-AD) and 6 large cell neuroendocrine carcinoma combined with AD (LCNEC-AD)), and 11 pleomorphic carcinoma with AD (PC-AD). After genomic DNA was extracted from separately microdissected paraffin-embedded tissues, mutation analysis of EGFR was performed using peptide nucleic acid-clamp real-time PCR-based assay in both AD and non-AD components.
Results: The detection rate for EGFR mutation was 31.6% (6 cases: 1 in exon 19 and 5 in exon 21) in 19 ADSQ patients, 11.1% (1 SCLC-AD case: 1 in exon 19) in 9 NE-AD patients, and 9.1% (1 case: 1 in exon 19) in PC-AD patients. Identical EGFR mutations were found in both AD and non-AD components in all 6 ADSQ cases and 1 SCLC-AD case, whereas EGFR mutation was detected in AD component, but not in non-AD component in PC-AD. Although the volume of AD tended to be larger (≥ 50%) in tumor with EGFR mutation than in tumor without EGFR mutation, no statistical significance was found. 
Conclusions:
We clarified that a subset of non-AD components contains EGFR mutations. In particular, ADSQ had a relatively high frequency of EGFR mutation. Thus, prospective identification of EGFR mutations in ADSQ, combined NE carcinoma and PC before the initiation of treatment is an essential step to identify which patient might benefit from targeted therapies, especially in advanced tumors which are not resected and where only small biopsies are available for molecular testing.
Lung Adenocarcinoma with Mucin-Related Antigen 4 Expression Is Associated with the Smoking Status and Poor Prognosis
Mariyo Rokutan, Akihiko Yoshizawa, Hironori Haga. Kyoto University Hospital, Kyoto, Japan. Background: Mucin-related antigen 4 (MUC4) is a transmembrane glycoprotein that functions in the cell growth signaling pathway. The expression of MUC4 has been studied in malignancies of various organs and is associated with a poor prognosis. However, the significance of MUC4 expression in lung cancer is unclear. The aim of this study was to analyze MUC4 expression in resected lung adenocarcinomas by using immunohistochemistry (IHC) to define the clinicopathological characteristics better. Design: Immunohistochemistry analysis of MUC4 was performed by using tissue microarray slides of 348 lung adenocarcinomas. Scoring was based on the distribution and intensity of staining (H score). A positive case was determined by considering an H score of 51-300 and a negative case by considering an H score of 0-50. The association between MUC4 expression and the following clinicopathological parameters was evaluated: sex; age; smoking status; tumor stage; tumor grade; lymph-vascular invasion; pleural invasion; expression of MUC5B, MUC5AC, MUC6, TTF-1, Cdx2, and MUC2 (based on IHC); and the mutation status of EGFR, KRAS, and HER2. Moreover, the survival rates were calculated using the Kaplan-Meier method.
Results: The expression of MUC4 was positive in 97 (27.9%) tumors. Most patients with MUC4 expression were men (p = 0.001) and smokers (p = 0.014). Moreover, MUC4 expression was significantly associated with solid adenocarcinoma (p < 0.001), high histological tumor grade (p = 0.001), and vascular invasion (p = 0.001), whereas it was not associated with age, tumor size, tumor stage, lymphatic invasion, pleural invasion, and IHC expression of MUC5B, MUC5AC, MUC6, TTF-1, Cdx2, and MUC2. The expression of MUC4 had a significant inverse correlation with EGFR mutation (p = 0.002), whereas its expression was not associated with mutations in KRAS or HER2. Patients with MUC4 expression had a significantly worse prognosis, with a 64.7% overall survival rate at 5 years, compared to patients without MUC4 expression (p = 0.023).
Conclusions:
The present study showed that lung adenocarcinomas with MUC4 expression tend to develop in male smokers, with a high grade tumor, and with the EGFR wild-type gene. Moreover, these patients tended to have a poorer prognosis. Taken together, lung adenocarcinoma with MUC4 expression can be a distinct phenotype caused by smoking. Background: In non--small cell lung cancer (NSCLC), the canonical EML4--ALK inversion results in a fusion protein with a constitutively active ALK kinase, which is associated with response to targeted inhibitors such as crizotinib. Clinically, anti--ALK therapy is often initiated based on evidence of an ALK rearrangement,-generally detected by fluorescent in situ hybridization (FISH) of interphase cells in FFPE tissue sections. However, FISH cannot differentiate between different ALK partner genes or non-canonical breakpoints, raising the possibility that not all ALK rearrangements are detected, and that not all detected ALK fusions may be responsive to targeted inhibitors. Indeed, "ALK positive" NSCLC has only a 60% objective response rate to ALK inhibitors. In this study we sought to determine if next generation sequencing (NGS) targeting DNA-level translocations could further define ALK rearrangements. Design: From a set of 1532 cases evaluated for an ALK rearrangement by interphase FISH, we identified 29 rearranged cases, of which 11 had concurrent clinical DNA NGS sequencing performed as part of routine patient care (via a hybrid capture based approach using paired 2x101bp reads). The sequencing included probes targeting ALK introns 16-22 in addition to other cancer-related genes. Rearrangements identified using the Breakdancer and ClusterFast software packages. Results: All 11 cases positive for ALK rearrangement by FISH showed evidence of the translocation by sequencing. Non--canonical breakpoints and rearrangement partners were identified in 4 of 11 cases (36%). In two of 4 cases the ALK rearrangement involved intergenic, noncoding DNA on chromosome 2; in the remaining 2 cases SPDYA--ALK and ASXL2--ALK fusions were detected. In the ASXL2-ALK fusion, despite having the canonical ALK intron 19 breakpoint, the genes are in opposing transcriptional orientation, suggesting no functional ALK kinase domain is transcribed. Overall, sequencing data predict three of these four translocations to result in a non-functional fusion protein.
Next Generation Sequencing Reveals Genomic
Conclusions: NGS-based testing demonstrates substantial genomic heterogeneity in ALK-rearranged NSCLC. NGS-based testing can resolve novel partner genes and noncanonical breakpoints, which may impart a different therapeutic response to targeted inhibitors. FISH testing for "ALK positive" lung adenocarcinoma underestimates the heterogeneity among ALK translocations.
Usefulness and Limitation of Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS) Specimen for PD-L1 Companion Diagnosis in Lung Cancer
Rie Sakakibara, Noriko Motoi, Hironori Ninomiya, Kentaro Inamura, Makoto Nishio, Yuichi Ishikawa. The Cancer Institute, Japanese Foundation for Cancer Research, Koto, Tokyo, Japan; Cancer Institute Hospital, JFCR, Koto, Tokyo, Japan. Background: For personalized cancer therapy, it is required to establish a suitable companion diagnostic strategy for an adequate molecular target. In lung cancer, it is often difficult to obtain enough tumor sample by a conventional transbronchial biopsy. For example, in order to enroll in clinical trial with programmed cell death-ligand 1 (PD-L1) target therapy, it is required to submit enough tumor (more than 100 tumor cells). In this study, we studied the potential usefulness of an endobronchial ultrasound transbronchial needle aspiration (EBUS) system which is a novel minimally invasive biopsy method recently introduced in Japan for companion diagnosis of PD-L1. Design: We collected consecutive 100 primary lung cancer cases diagnosed by EBUS procedures between 2013 and 2014. We evaluated numbers of tumor cells and total nuclear cells in each specimen. First, we counted by eye-ball on HE stained slides. Then, we calibrated tumor cells by combination of immunohistochemical tumor markers ( TTF1 as adenocarcinoma (Ad), p40 as squamous cell carcinoma (SqCC) and synaptophysin as neuroendocrine carcinoma (NEC) markers) with an automated image calibration system using an Aperio Image Scope (Leica systems). We also assessed PD-L1 immunohistochemical (IHC) expression in both EBUS and corresponding surgical resected specimens. The PD-L1 membranous IHC expressions were scored as 0,1,2,3. Results: Pathological diagnoses of 100 cases were as following; 53 Ad, 17 SqCC and 27 NEC. The median (and range) number of tumor cells in all/ Ad/ SqCC/ NEC cases were 1337 (8-6000)/ 1140 (81-6910)/ 878 (158-3835)/ 4620 (146-60000) by eye-ball counting, and 1851 (0-59120)/ 1531 (1-44224)/ 4243 (0-17065)/ 3157 (11-59120) by automated image calibration. The eye-ball counting and automated image calibration showed good correlation. All but one cases (99%) had sufficient numbers of tumor cell for enrollment of PD-L1 clinical study. The results of PD-L1 IHC score in EBUS and surgical specimen showed good concordance. All EBUS case with corresponding surgical resected specimen resulted more than score 1 in this study. The PD-L1 IHC expression degree (proportion and/or intensity) was heterogeneous in surgically resected specimen. Conclusions: Our study revealed EBUS specimens can be useful for companion diagnosis of PD-L1 in case with IHC positive cases, but it should be mentioned as a critical limitation of possibility of false negative cases due to intratumoral heterogeneity.
Detection of BRAF Mutation in Lung Adenocarcinoma by NextGeneration Sequencing: Beyond V600E Mutation
Kevan Salimian, Roghayeh Fazeli, Gang Zheng, Zahra Maleki. The Johns Hopkins Hospital, Baltimore, MD. Background: Molecular identification of driver mutations in lung adenocarcinomas (ACA) has changed the landscape of management. EGFR mutation and ALK translocation in lung ACA predict favorable responses to targeted therapy and have been fairly well studied. BRAF mutations have also been described in a small subset of lung ACA. We devised this study to analyze the histologic and cytomorphologic features of BRAF-mutated lung ACA, along with the clinical characteristics of patients presenting with this entity. Design: We performed a retrospective review of all surgical pathology and cytopathology specimens at Johns Hopkins from January 2013 to January 2015 that contained BRAF-mutated lung ACA detected by next-generation sequencing (NGS). Patient demographics, clinical history, ACA morphology, and molecular studies were assessed and stratified based on BRAF mutational status (V600E vs non-V600E).
Results: Ten patients harbored V600E mutations and 26 patients carried non-V600E mutations. The mean age was similar for both groups. V600E mutation was more common in females (90%). Smoking showed strong correlation with BRAF mutation in both groups (90% or greater). While both groups shared a variety of morphologic patterns, lepidic and mucinous were more common in the non-V600E group. Both groups showed variable differentiation and tumor staging. Both groups were immunoreactive for TTF-1 and Napsin A but negative for P40. The V600E group harbored an AKT mutation in two cases and a PIK3CA mutation in one case. The non-V600E group contained a KRAS mutation in four cases and a PIK3CA mutation in one case. Non-V600E mutations included D594 (n=7), G469 (n=5), G466 (n=4), K601E (n=3), G596 (n=2), G464V (n=2), and one each of Q609L, E611Q, and T4401. No ALK rearrangement was detected in either group in available cases.
Conclusions: Mutated-BRAF lung ACA tend to arise in older patients with the vast majority being current or former smokers. The V600E mutation was present in slightly less than 30% of cases which could have therapeutic promise. BRAF mutations were infrequently found in combination with other common lung ACA driver mutations. The histologic grade and architecture of these tumors varied significantly. NGS has made it possible to detect more BRAF mutations in addition to V600E. Further investigation is warranted to evaluate the role of non-V600E mutations in patients with lung ACA. Background: Endometrial adenocarcinoma (EAC) metastatic to the lung poses diagnostic challenges, particularly when the primary tumor is not known. The use of TTF-1 can potentially be misleading as it can be positive in up to 19% of endometrial carcinomas. Although the use of PAX8 to evaluate metastatic Müllerian carcinomas is well established, PAX8 is also positive in thyroid and renal cell carcinomas. Therefore, there is utility in identifying additional markers for metastatic endometrial cancer. Sry-related HMG box transcription factor 17 (SOX17) plays an important role in embryogenesis and development, and we have previously shown its expression in EAC. The purpose of this study is to evaluate SOX17 expression in lung cancer to determine whether it can be used as a diagnostic marker to differentiate primary lung adenocarcinoma from metastatic EAC. Design: TMAs including 129 primary lung adenocarcinoma cases, 98 primary lung squamous cell carcinoma cases, and 36 cases of primary EAC were stained for SOX17. Subsequently, whole sections of 11 primary EAC cases and 10 metastatic EAC cases, including 4 metastatic to the lung, were stained for SOX17. A case was considered to be SOX17 positive if more than 10% of tumor cells showed moderate nuclear expression. Results: All lung adenocarcinomas and squamous cell carcinomas were distinctly negative for SOX17. In contrast, 72% (26/36) of EAC TMA cases were SOX17 positive. 100% (11/11) of primary EAC whole section cases showed weak to moderate nuclear SOX17 positivity in at least 30% of tumor cells. All 10 metastatic EAC whole section cases showed moderate to strong nuclear SOX17 positivity in at least 50% of tumor cells. Overall, metastatic EAC had stronger staining and more SOX17 positive tumor cells than primary EAC. Conclusions: In this pilot study, SOX17 has been shown to be expressed in both primary and metastatic EAC, but distinctly absent in primary lung adenocarcinoma and squamous cell carcinoma. Therefore, SOX17 is a useful diagnostic marker to differentiate metastatic EAC from primary lung carcinoma. Further study of its diagnostic utility in a larger series and as a member of an IHC panel including PAX8 and ER is underway.
Usefullness of p16 Immunostain and Molecular Testing for HPV in Determining Primary Versus Metastatic Squamous Cell Carcinoma in the Lung
Jamie Steinmetz, Brett E Close, Larissa V Furtado, Aliya N Husain, Nicole A Cipriani. University of Chicago, Chicago, IL. Background: Primary lung squamous cell carcinoma (PLSCC) and metastatic squamous cell carcinoma (MSCC) to the lung can be morphologically indistinguishable, especially in the absence of a pulmonary in-situ component or central scar. A common clinical question is whether, in patients with primary head and neck carcinoma (HNSCC) or cervical SCC, a pulmonary SCC represents a metastasis or a second primary. If a primary HN or cervical SCC is HPV-associated, HPV status of the lung tumor could be useful. The aim of this study was to determine the rates of positivity of p16 IHC and presence of HPV DNA in PLSCC, in order to determine if p16/HPV status could be useful as an indicator of metastasis in the proper clinical context. Design: 23 PLSCC cases were identified in patients with no known history of HN or cervical carcinoma. A tissue microarray of these cases was stained with p40 and p16 immunostains. p40 was considered positive if diffuse nuclear staining was present.
Any p16 staining was noted. Multiplex qPCR assay (which detects HPV subtypes 16, 18, 31, 33, 45, 52 and 58) was performed on all available cases with any p16 staining. Additionally, our records were searched for lung SCC cases in which there was a known HPV-associated HN or cervical primary. Results: All 23 PLSCC cases showed p40 positivity. 35% (8/23) PLSCCs showed some staining with p16 (4 cases with moderate-strong nuclear and cytoplasmic staining in >80% of tumor cells, 2 with weak-moderate nuclear and cytoplasmic staining in 60%, 2 with only cytoplasmic staining (1 weak <50%, 1 moderate 70%)). Multiplex qPCR assay was performed on the 7 available cases with p16 staining and all were negative. Record search revealed two cases of lung SCC in patients with prior HPV-associated HNSCC or cervical SCC: one tonsillar SCC with lung metastasis, both of which were positive for p16 and HPV16 DNA; one uterine cervical SCC with lung metastasis, in which the lung SCC was positive for p16 and HPV45 DNA. The primary cervical tumor was not available for testing. Conclusions: We conclude that staining for p16 alone in SCC in the lung should not be used as an indicator of the presence of HPV DNA, and is not helpful in distinguishing PLSCC from MSCC. p16 IHC may be helpful when a HN or cervical SCC is p16 positive and the lung tumor is p16 negative. In the context of a HN or cervical SCC, molecular testing showing the same HPV DNA in the primary and lung tumor is the best evidence for metastasis. Rachel Stewart, Dava West, Chi Wang, Heidi Weiss, Tamas Gal, Eric Durbin, William O'Connor, Min Chen, Kathleen L O' Connor. University of Kentucky, Lexington, KY. Background: Lung cancer carries a poor prognosis and is the most common cause of cancer-related death worldwide. The integrin α6β4 is a laminin receptor that has been implicated in promoting carcinoma progression by cooperating with growth factor receptors and amplifying downstream signaling pathways such as PI3K, AKT, and MAPK. In carcinoma cells with mutant TP53, the integrin α6β4 promotes cell survival. TP53 mutations and integrin α6β4 overexpression co-occur in many aggressive malignancies. Given that lung squamous cell carcinoma is an aggressive malignancy with a high frequency of TP53 mutations, we predicted that integrin α6β4 expression in this tumor type would associate with poor prognosis. Design: In order to investigate integrin α6β4 expression as it relates to clinicopathologic features and patient survival in non-small cell lung cancer (NSCLC), we constructed a lung cancer tissue microarray (TMA) (N = 211). TMA sections were stained for expression of the integrin β4 subunit using immunohistochemistry. In addition, we analyzed multiple external gene expression datasets (TCGA, Hou) for integrin β4 expression. Results: Using our TMA data, we found that integrin β4 expression is elevated in squamous cell carcinomas when compared to adenocarcinomas (P < 0.0001), which was confirmed in external gene expression datasets (P < 0.0001). We also found that integrin β4 overexpression is associated with the presence of venous invasion (P = 0.0032), and with reduced overall survival (Hazard ratio 1.457, 95% confidence interval 1.013 to 2.094, P = 0.0422) among patients with NSCLC. Integrin β4 mRNA overexpression was also shown to associate with reduced overall survival in a TCGA NSCLC dataset (Hazard ratio 1.714, 95% confidence interval 1.052 to 2.792, P = 0.0305). Using cBioPortal, we generated a network map demonstrating the 50 most highly altered genes neighboring ITGB4 in squamous cell lung cancer. These genes included various laminins, collagens, CD151, EGFR, PIK3CA, MET, and YES1.
Elevated Integrin α6β4 Expression Is Associated with Venous Invasion and Decreased Survival in Squamous Cell Lung Cancer
Conclusions:
In conclusion, we demonstrate that integrin β4 is overexpressed in lung SCC, and that it is an adverse prognostic marker. Background: The NCCN guidelines for lung cancer patients with metastatic disease recommend that EGFR mutation and ALK rearrangement studies should be performed as part of a multiplex or next-generation sequencing (NGS) panel that also includes testing for BRAF and ERBB2 mutations, MET amplification and ROS1 and RET rearrangements. Comprehensive genomic profiling (CGP) is a hybrid capture-based NGS test that can detect genomic alterations (GA) in hundreds of cancer-related genes efficiently, rapidly and accurately. Our aim is to investigate the feasibility and utility of CGP in clinical practice. Design: DNA was extracted from 40 microns of FFPE sections from 7493 consecutive cases of lung adenocarcinoma, adenosquamous carcinoma, NSCLC-NOS and large cell carcinoma . CGP was performed using a hybrid-capture, adaptor ligation based NGS assay to a mean coverage depth of 572X. GA (point mutations, small indels, copy number changes and rearrangements) involving EGFR, ALK, BRAF, ERBB2, MET, ROS1, RET and KRAS were recorded for each case. In addition to patient age, sex and histologic type, the tissue sample site was reviewed for each case. Results: The median age was 64 years (range 14-88) and 58% were female. In this series, 5928 (79%) lung adenocarcinomas, 85 (1%) adenosquamous carcinomas, 1440 (19%) NSCLC-NOS and 40 large cell carcinomas (0.5%) were tested by CGP. 47% of specimens were obtained from extra-pulmonary metastatic sites. Overall, 5346 (71%) patients harbored at least one GA involving EGFR (20%), ALK (4.0%), BRAF (5.7%), ERBB2 (5.7%), MET (5.2%), ROS1 (1.5%), RET (2.4%) and KRAS (32%). A minority of patients harbored multiple GA in one or more of these genes, likely attributable to resistance mutations. The difference in the numbers of adenocarcinomas (75%) and adenosquamous carcinomas (69%) with at least one of the GA listed above versus NSCLC-NOS (58%) and large cell carcinoma (42%) was statistically significant (p-value < 0.0001). Conclusions: CGP is practical and facilitates implementation of the NCCN guidelines for lung cancer biomarker testing by enabling efficient, rapid and accurate detection of GA involving all seven driver oncogenes listed by NCCN and KRAS. Furthermore, this study reinforces tissue-based NGS testing as the gold standard to which other types of assays can be compared for evaluation of sensitivity and specificity.
Comprehensive Genomic Profiling of Lung Cancer is Practical and
Janus Kinase 3 (JAK3) Aberrations in Non-Small Cell Lung Cancer
Laura N Toth, Christopher I Amos, Konstantin H Dragnev, Gregory J Tsongalis, Laura J Tafe. Dartmouth-Hitchcock Medical Center, Lebanon, NH; Norris Cotton Cancer Center, Lebanon, NH. Background: Janus kinase 3 (JAK3) is a cytoplasmic tyrosine kinase expressed in cells of hematopoietic origin and mediates response to certain cytokines by activation of the STAT pathway. JAK3 mutations are associated with the development of some types of leukemia and have been reported at a low frequency in solid tumors. A recent report suggests that JAK3 activation in lung cancer cells induces PD-L1 expression, an important target of immunotherapy. In this study, we examine the prevalence and features of non-small cell lung cancers (NSCLC) with JAK3 mutations. Design: In May 2013 our laboratory began using the Ion Torrent PGM and the AmpliSeq Cancer Hotspot Panel v2 for clinical practice. Briefly, DNA was extracted from unstained FFPE slides with a minimum tumor cellularity of 10%. DNA was quantified using the PicoGreen method. Barcoded libraries were prepared using up to 10ng of DNA; sequencing was performed on the Ion Torrent PGM (318 chip). Variants were identified using the Ion Torrent Variant Caller Plugin and reference genome hg19. Golden Helix's SVS software was used for annotation and prediction of the significance of the variants. Tumor tissue was also tested for PD-L1 expression by immunohistochemistry (IHC) using PD-L1/CD274 monoclonal antibody (clone SP142) (Bioscience). Results: Out of 288 NSCLC cases successfully sequenced between May 2013 -December 2014, 8 (2.8%) harbored a JAK3 c.2164G>A (p.V722I) mutation. The patients had a median age of 67.5 years and six of the patients were female (75%). Five were current smokers, 2 former smokers, and 1 a non-smoker with significant second-hand exposure. Five patients presented with stage IV disease with CNS metastases; 4 are deceased, 1 is lost to follow up. In 5 instances (63%), the tumors also had a KRAS mutation (p.G12C in 4, p.G12V in 1). Additional mutations were identified in KIT (1), MET (1), PDGFRA (1), STK11 (2), andTP53 (3). Tissue was available for IHC in 6 cases, only two of which showed PD-L1 expression in >5% of tumor cells. Conclusions: Recurrent JAK3 p.V772I mutations are found in a subset of NSCLCs, often associated with known smoking related KRAS mutations. The mutations occur in exon 15 which encodes for the JH2 pseudokinase domain of JAK3. Additional studies are needed to understand the functional effect of JAK3 mutations in the development of NSCLC and the potential implications for immunotherapy or JAK3 inhibitors.
Histologic Patterns of Resected Lung Adenocarcinoma Brain Metastases and Correlation with Molecular Analysis
Laura N Toth, Laura J Tafe. Dartmouth-Hitchcock Medical Center, Lebanon, NH. Background: Metastatic disease to the brain is common in patients with advance stage lung non-small cell carcinoma. Treatment of brain metastases may include chemoradiation, stereotactic ablative radiosurgery or tumor resection. To our knowledge, there have been limited studies that examine the histologic patterns of resected lung adenocarcinomas (ADC) and correlate with molecular analysis. Design: We examined 29 consecutive cases of surgically resected brain metastases from 2012-2014 and classified the morphology according to the 2015 WHO classification while also including the recently recognized cribriform pattern of acinar which is associated with poor prognosis. Molecular genotyping had previously been performed either by single gene assays for EGFR, KRAS and BRAF (prior to 2013) or by next generations sequencing (NGS) with the 50 gene AmpliSeq Cancer Hotspot Panel v2 (Ion Torrent). This testing was done on the brain metastasis (23), lung primary (4) or a lymph node metastasis (2). Histology was reviewed without knowledge of mutation status. Results: Of the 29 cases, the predominant histologic variant was the solid type (59%, 17 cases) followed by papillary (14%, 4 cases) and cribriform (14%, 4 cases). Less commonly appreciated were the micropapillary (2 cases), and one case each of acinar, and colloid patterns. Mutations in TP53 and KRAS were the most frequently identified (13 and 11, respectively). Seven of the KRAS mutations were seen in tumors with solid pattern. Interestingly, none of the cases with cribriform or micropapillary patterns harbored KRAS mutations, however, this was only 6 cases. NGS testing identified clinically important mutations that would have gone undetected with single gene analysis including an EGFR ex 20 insertion, ERBB2 ex 20 insertion and two PIK3CA mutations. Conclusions: Perhaps not surprisingly, in this patient cohort who underwent surgical resection of brain metastases, the majority of tumors showed what are considered aggressive morphologic patterns (solid, cribriform and micropapillary; N = 21) and frequent KRAS mutations. The next phase of this study will compare the metastatic tumors to the primary lung cancers when available and correlate with patient characteristic, treatment and outcome. Understanding the histopathology of lung ADC brain metastases can potentially help guide treatment and perhaps contribute to, ultimately, the prevention of brain metastases. Humberto Trejo Bittar, Daniel Doberer, Mitra Mehrad, Sally Wenzel, Samuel A Yousem. University of Pittsburgh Medical Center, Pittsburgh, PA. Background: Severe asthmatic patients suffer from a disease that is poorly understood and uncontrolled with traditional therapy. The histologic changes occurring in ATS/ERS defined "severe asthma", particularly at the level of the distal airways remain largely unknown. We aimed to describe the morphologic changes in the distal lung in these severe asthmatics studied by video-assisted thoracoscopic surgery (VATS) lung biopsies. Design: 43 VATS biopsy specimens from "treatment-resistant severe asthma" (TRSA) patients were available for histologic examination. Histologic variables studied included goblet cell metaplasia, basement membrane thickness, airway inflammatory infiltrates and muscle thickness, alveolar septal infiltrates and presence and location of granulomas. Final pathological observations were correlated with clinical presentation and serological data. Results: Of the 43 "TRSA" cases, 4 (9%) showed non-asthma related pathology (3 hypersensitivity pneumonitis (HSP), 1 chronic aspiration). The remaining 39 cases demonstrated conventional histologic findings of asthma often with intense lymphocytic bronchiolitis (LB) (16/39 = 41%), asthmatic granulomatosis (AG) (20/39 = 51%), and non-diagnostic airway changes (3/39 = 8%). Unexpectedly, 22 of 39 (56%) of TRSA patients had non-disease defining autoantibodies or a family history of autoimmune disease (AID), among which 13 (59%) presented with AG; whereas in those without history of AID, only 41% (7/17) had evidence of AG. Conclusions: Histologic examination of VATS lung biopsies in "TRSA" demonstrates diverse pathologic findings including other diagnoses (HSP and aspiration). AG was present in 51% of TRSA patients; therefore pathologists should be aware of this new pathologic entity. Importantly, history of AID was present in 56% of TRSA patients, of which 59% (13/22) were diagnosed as AG. Our data suggest that histologic findings in TRSA patients, might represent a hybrid of asthma and lung involvement by AID; therefore, VATS lung biopsies should be considered to identify patients who will benefit from treatment options beyond conventional corticosteroids. . Results: 69% of SCLC cases (20 of 29) showed >1% PD-L1 positivity within tumor cells. PD-L1 expression showed significant correlation with TILs expressing PD-1 (r=0.797, P < 0.001) and CD3 (r=0.759, P < 0.001). Patients' outcome analysis using Kaplan-Meier showed that PD-L1 expression (>1% of positive cells) correlated with better overall survival (OS; P=0.001, univariate analysis). PD-L1 expression using others different cutoff (5%, 10%, 20%) did not have any significant correlation with OS. Conclusions: Our data shows that majority of SCLC have >1% positive PD-L1 expression, by immunohistochemical analysis and contain PD-1 positive T-cells. Further study of PD-L1 as a prognostic factor and potential target for therapy is warranted. Background: Small cell lung carcinoma (SCLC) is characterized by brisk tumor proliferation, high mutational frequency, and RB1 and TP53 loss of function, while typical (TC) and atypical carcinoids (AC) show low proliferation and lack mutations in these genes. Pulmonary large cell neuroendocrine carcinoma (LCNEC) has a high proliferation rate (>10 mitoses/mm2), but a better prognosis and more heterogeneous molecular profile than SCLC. A subset of tumors that resemble AC but have >10 mitoses/ mm2 are classified as LCNEC per the World Health Organization (WHO); however, evidence supporting this classification is lacking. We examine the clinical and genomic features of these "borderline" LCNEC (BT). Design: Included were TC and AC (grouped hereafter as low grade tumors, LG);BT; and LCNEC and SCLC (grouped as high grade tumors, HG) resected between 2013 and 2015 and classified according to WHO 2015 criteria. Targeted hybrid capture next generation sequencing for 309 cancer-related genes was performed for detection of single nucleotide variants (SNVs), copy number variants (CNV) and rearrangements. Results: 59 tumors including 9 TC, 7 AC, 7 BT, 11 LCNEC, and 25 SCLC were obtained from 31 women and 27 men. Patients with LG and BT were younger (56.8 and 56.4 vs 65.6 years, p=0.01), less frequently smokers (9, 56% and 2, 29% vs. 33, 94%; p=0.001), and smoked fewer pack-years (8.9 and 8.3 vs 50.4, p<0.0001) than patients with HG. BT and HG had higher numbers of SNVs compared to LG, (3.1 vs 6.1 vs 9.7 in LG, BT, and HG, p<0.0001), but BT and LG had significantly fewer gene-level CNVs than HG (29.1 vs 38 vs 68 in LG, BT, and HG, p=0.0013). 9 (82%) LCNEC and 23 (92%) SCLC had loss-of-function alterations in TP53 and/or RB1, while no TC, AC, or BT had these alterations. Other mechanisms of cell cycle dysregulation were seen in BT including CDKN2A deletion (n=1) and CCND1 amplification (n=1). Oncogenic alterations typical of lung adenocarcinoma were detected in 4 LCNEC (EGFR, KRAS, MET), one BT (AKT1+BRAF),one SCLC (EGFR), and no TC or AC. MEN1 mutations were seen in 2 (28%) AC, 1 (14%) BT and 1 (9%) LCNEC. Conclusions: Borderline tumors show a diverse profile of oncogene and tumor suppressor gene alterations. They are distinct from LCNEC in their younger age of onset, lack of a significant smoking association, absence of TP53 and RB1 alterations, and less pronounced copy number instability. These findings may have significant implications for selection of therapy and should be taken into consideration in pathologic classification. Background: Human papilloma virus (HPV) has been reported as a potential cause in some cases of lung cancer. A few previous studies report from 6-24% of non-small cell carcinomas to be positive for HPV with high risk HPV 16 and 18 genotypes. We performed molecular studies to determine the prevalence of HPV positivity in squamous cell carcinomas of the lung and to determine the most common genotypes. Design: Pulmonary squamous cell carcinomas and HPV positive cervical formalinfixed paraffin-embedded (FFPE) tissue samples with corresponding H&E slides were analyzed. All cases had 20µm sections prepared and mounted onto microscopic slides. They were then macrodissected to remove the tumor area that was marked on the corresponding H&E slides. The sections of tumor were stored in microcentrifuge tubes in a -20° C freezer until DNA extraction could be competed. The Qiagen QIAamp DNA FFPE Tissue Kit was used to extract and purify the tumor DNA. The DNA was then quantitated using a spectrophotometer in preparation for PCR amplification using the INNO-LiPA HPV Genotyping Extra AMP Kit. After PCR amplification, the biotinylated lung DNA samples were tested for HPV using the INNO-LiPA HPV Genotyping Kit. One HPV positive cervical sample was used as a second positive control for each run in addition to the kit positive control. Water was utilized as a negative control in each run to ensure that there was no cross-contamination from HPV positive DNA. This kit is capable of identifying 32 individual HPV genotypes. Results: One squamous cell carcinoma lung sample out of 68 tested positive for HPV. The lung sample was a 4.0cm chemonaive stage IB cancer which tested positive for HPV genotype 11, a low risk genotype, establishing a study prevalence of 1.5% in squamous cell carcinoma.
Histologic Findings of Video-Assisted Thoracoscopic Surgery Lung Biopsies Performed in Patients with Treatment-Resistant Severe Asthma
Expression of Programmed
HPV Prevalence and Genotype in Squamous Cell
Conclusions:
The prevalence of HPV positivity in squamous cell carcinoma of the lung is much lower in our series (1.5%) than previously reported. Based on the study results, we believe that HPV DNA is uncommonly associated with squamous cell carcinoma of the lung.
PD-L1, PD-1, CD4 and CD8 Expression in Neoplastic and NonNeoplastic Thymus
Ann E Walts, Alberto M Marchevsky. Cedars-Sinai Medical Center, Los Angeles, CA. Background: The ability of tumor cells to express PD-L1, programmed cell death protein-1, which binds with its receptor PD-1 on activated T-cells helps tumors avoid detection and allows for tumor growth and/or metastases. There is only limited information regarding the expression of PD-L1 and PD-1 in thymic epithelial tumors (TET). Design: Serial sections from 38 thymomas (WHO type A (n=2), AB (n=9), B1 (n=9), B2 (n=8), B3 (n=10), 8 thymic squamous carcinomas (SqCA), and 20 non-neoplastic thymi (adjacent to the tumors (n=16), hyperplastic (n=2), and normal of childhood (n=2)) were stained with antibodies against PD-L1 (clone SP142 Spring Bioscience), PD-1 (MRQ22 Cell Marque), CD4 (clone SPO32 Cell Marque), and CD8 (JCB117 Ventana). Membranous and/or cytoplasmic staining for PD-L1 and PD-1 in ≥ 5% of thymic epithelial cells, tumor cells or lymphocytes was scored as positive. Results: PD-L1 was expressed in 55% of non-neoplastic thymi, 22%-100% of thymomas and 37.5% of SqCA. PD-L1 expression in TET was equal to or higher than that seen in adjacent non-neoplastic thymi in 75% of paired cases. A significantly higher (p<0.02) proportion of B2 (100%) and B3 (90%) thymomas were positive for PD-L1 than non-neoplastic thymi, A, AB and B1 thymomas and SqCA. PD-1 was expressed in 10%-22.2% of cases. There was no significant difference (p>0.05) in the proportion of PD-1 positive cases by diagnosis, and PD-1 expression did not appear to correlate with PD-L1 expression within individual cases or across diagnostic groups. PD-L1 expression was diffuse and predominantly seen in epithelial cells while PD-1 expression was often observed in scattered and/or small groups of lymphocytes and/or in germinal centers. TET contained variable numbers of CD4+ and CD8+ lymphocytes, according to WHO type. CD4+ cells were generally concentrated at the periphery of neoplastic epithelial cells in B2 and B3 thymomas and SqCA; CD8+ lymphocytes were diffusely admixed with the epithelial tumor cells of these lesions.
Conclusions: PD-L1 expression is more frequent in B2 and B3 thymomas than in other TET, including SqCA, and non-neoplastic thymi. PD-L1 expression does not appear to correlate with PD-1, CD4 or CD8 expression, raising the possibility that the PD-L1/ PD-1 checkpoint pathway may not play a major role in TET. Design: Paraffin embedded cell block sections from 63 pleural and 4 peritoneal effusions from 32 patients with biopsy confirmed MM and 35 with reactive effusions were stained using a monoclonal antibody against BAP1 (clone 4, Santa Cruz Biotech.). 38 (56.7%) of the 67 cell blocks (17 MM and 21 reactive) were also analyzed for p16 deletion by FISH. Only mesothelial cells exhibiting atypical morphology were evaluated. Criteria for MM were: absence of nuclear staining for BAP1 in > 50% of the atypical mesothelial cells in the presence of a positive internal control, p16 homozygous deletion in > 15% or hemizygous deletion in > 41.5% of atypical mesothelial cells analyzed (Wu et al. AJCP 2013; 139:39-46) . Sensitivity (SS), specificity (SP), and positive and negative predictive values (PPV, NPV) for the diagnosis of MM were calculated for each test. Results: 17 of 32 MM were correctly diagnosed by BAP1 IHC. The SS, SP, PPV, NPV of BAP1 IHC for MM were 53.1%, 85.7%, 77.3%, and 64.3%, respectively. In the 38 cases studied by IHC and FISH, the SS, SP, PPV, and NPV of IHC for MM were 41.2%, 81.0%, 63.6%, and 63.0%, respectively. 7 of 17 MM were diagnosed by FISH; 6 showed homozygous and 1 hemizygous deletion patterns. SS, SP, PPV, and NPV of FISH for MM in these 38 cases were 41.2%, 100%, 100%, and 67.7%, respectively. 10 of the 15 false negative cases by BAP1 IHC were also studied by FISH: 6 were also false negative by FISH and 4 were diagnosed correctly by FISH. 4 of the 5 false positive cases by BAP1 IHC were studied and correctly diagnosed by FISH. 2 MM correctly diagnosed by FISH were false negative by IHC. Conclusions: BAP1 IHC and p16 FISH yield similar sensitivities for MM in paired samples but FISH has a higher specificity. As IHC is more readily available and easier to interpret in most laboratories, BAP1 IHC to screen effusions with atypical mesothelial cells and confirmation by FISH provides a cost effective algorithm for diagnosis of these cases. This strategy would reduce the number of cases requiring FISH analysis without significant differences in NPVs. Background: Thymomas are rare neoplasms of the anterior mediastinum. Atypical thymoma (AT)(WHO type B3) is an infrequent subtype of thymoma characterized by an epithelial-rich histology with limited immature T lymphocytes. Pure AT are uncommon as the majority of thymomas demonstrate mixed histology if sufficiently sampled. Lack of stratification by histologic type has prevented large scale research into these tumors and focused studies on this tumor type are lacking. We report the clinicopathological features of 25 such tumors, in one of the largest series of these tumors to date. Design: Twenty-five cases of pure AT from the surgical pathology files of the MD Anderson Cancer Center were analyzed after review of 400 thymic epithelial neoplasms and after exclusion of cases with merely an AT component. An average of 10 tumor sections from thymectomy specimens was available for review in each case; cases with fewer than 5 sections were excluded from this study. Clinical information including presentation, treatment and follow up was obtained from the referring pathologists or institutional clinical files. Results: The patients were 11 females and 14 males with an age range from 19 to 75 years (mean, 54). Main presenting symptoms included chest pain, shortness of breath and dyspnea. Myasthenia gravis was present in 7 patients. The average tumor size was 7.2 cm. Histologically, the tumors were characterized by a lobulated epithelial proliferation with mild to moderate cytologic atypia, occasional perivascular spaces and scarce infiltrate of T cells. Using Moran's staging schema, 11 patients were stage I, 5 stage 2a, 6 stage 2b and 1 stage 3a and 3b, respectively. Sixteen patients received neoadjuvant and/or adjuvant chemoradiation. Clinical follow-up available for 22 patients showed that 15 were alive with a follow-up period from 5-140 months (mean, 54), 7 of which with stable recurrent and/or metastatic disease. Seven patients had died 24-172 months after diagnosis (mean, 87), 3 from unrelated causes. Conclusions: Pure AT are tumors predominantly affecting patients in the 6 th decade of life with a slight male predilection. Although AT are widely regarded as an intermediate form between thymoma and thymic carcinoma, its clinical course is characterized by a low grade malignant behavior that is not much different from that of other types of thymoma. Although histology is important, the most relevant predictor of prognosis remains tumor stage at the time of diagnosis. The use of the Moran staging system appears to provide clear and direct pathological information with regard to the degree of invasiveness of the tumor.
BAP1 Immunostain and P16 FISH: Clinical Applicability to Confirm Malignant Mesothelioma in Effusions
